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ABSTRACT 
This is a descriptive retrospective study about thyroid tumors in Sudanese patients. It 
was carried out in the period from January 2006 to December 2008.The study was 
conducted in the three main histopathology laboratories in Sudan, the National Health 
Laboratory (NHL), Radiation and Isotope Center-Khartoum (RICK), and Soba 
University Hospital (SOH).  
 
The study aimed at determining the histopathological pattern of thyroid tumors and to 
show the distribution of age, sex, risk factors, origin, ethnic groups, and clinical 
presentation of these tumors. 
 
Ninety seven (97) cases of thyroid tumors were analyzed in the study. The age of the 
patients ranged between 12 to 80 years with a mean of 37.54+14.72 years. The 
commonest age group was 30 to <40 years (27.8%).Females constituted 86.6% of the 
patients, with a male to female ratio of 1: 6.5. 
The study revealed that the prevalence of follicular adenoma in goitrous patients was 
7.5%, and that of malignant thyroid tumors was 2.9%. Follicular adenoma was the 
most common thyroid tumor constituting 72.2% of all thyroid tumors. Papillary 
carcinoma came next (12.4%) then follicular carcinoma (9.3%). Medullary carcinoma 
(3.1%) and anaplastic carcinoma (3.1%).   
Follicular adenoma occurred most commonly in adults aged 20 to <50 years 
(78.6%).The male to female ratio was 1: 7.75. 
The age group > 20 to < 50 was the commonest age group affected by malignant 
thyroid tumors (55.5%). No malignant thyroid tumors was diagnosed in age group 
<11 years. As a conclusion, the study showed that thyroid cancers occurred most 
commonly in young and middle aged adults and was rare in children.  
Regarding the grading of thyroid malignancies 52% of thyroid cancers in the study 
were of low grade malignancy, 37% were intermediate grade malignancy and 11.1% 
were of high grade malignancy. 
The study revealed that the percentage of malignancy diagnosed by FNABs was 
35.7%. Benign category constituted 50% and the indeterminate/suspicious category 
constituted 14.3%.  
The evaluation of thyroid tumors according to geographic regions, among ethnic 
groups and the correlation with risk factors could not be obtained as these data were 
not documented in the request forms. This entails urgent intervention otherwise 
thyroid tumor epidemiology will continue to be deficient. 
When all the findings in the study are compared together, it can be concluded that the 
histological pattern of thyroid tumors, the sex and age distributions in the study tend 
to correspond with studies in other countries. 
 
 ﻣﻠﺨﺺ اﻻﻃﺮوﺣﺔ
 ﺣﺎﻟﺔ  ﻣѧﻦ ﺣѧﺎﻻت أورام اﻟﻐѧﺪة اﻟﺪرﻗﻴѧﺔ ﻟѧﺪي ﻣﺮﺿѧﻲ ﺳѧﻮداﻧﻴﻴﻦ 79 أﺟﺮﻳﺖ ﻋﻠﻲ ﻋﺪد  هﺬﻩ دراﺳﺔ ﻗﻬﻘﺮﻳﺔ 
و ﻣﺴﺘѧﺸﻔﻲ ( إﺳѧﺘﺎك )ﻓﻲ آﻞ ﻣﻦ اﻟﻤﻌﻤﻞ اﻟﺼﺤﻲ اﻟﻘﻮﻣﻲ ،  م 8002 وﺣﺘﻰ دﻳﺴﻤﺒﺮ 6002وذﻟﻚ  ﻓﻲ اﻟﻔﺘﺮة ﻣﻦ ﻳﻨﺎﻳﺮ 
  .اﻟﺴﻮدان-اﻟﻌﻼج ﺑﺎﻷﺷﻌﺔ واﻟﻄﺐ اﻟﻨﻮوي و ﻣﺴﺘﺸﻔﻲ ﺳﻮﺑﺎ اﻟﺠﺎﻣﻌﻲ ﺑﺎﻟﺨﺮﻃﻮم
ﺗﻬﺪف هﺬﻩ اﻟﺪراﺳﺔ إﻟﻲ ﺗﺤﺪﻳﺪ اﻟﻨﻤﻂ اﻟﻨﺴﻴﺠﻲ اﻻﻣﺮاﺿѧﻲ ﻷورام اﻟﻐѧﺪة اﻟﺪرﻗﻴѧﺔ اﻟﺤﻤﻴѧﺪة واﻟﺨﺒﻴﺜѧﺔ ﻣﻨﻬѧﺎ، 
  .وﺗﻮﺿﻴﺢ ﺗﻮزﻳﻊ آﻞ ﻣﻦ اﻟﻌﻤﺮ ،اﻟﺠﻨﺲ ،اﻷﺻﻞ ،ﻋﻮاﻣﻞ اﻟﺨﻄﻮرة واﻟﻌﻼﻣﺎت اﻟﺴﺮﻳﺮﻳﺔ
ﺮﻳѧﺔ اﻷآﺜѧﺮ  ﻋﺎﻣѧﺎ، وآﺎﻧѧﺖ اﻟﻔﺌѧﺔ اﻟﻌﻤ 08-21 ﺣﺎﻟﺔ ﻣﺮﺿﻴﺔ ﺗﺮاوﺣﺖ أﻋﻤﺎرهﻢ ﻣѧﺎ ﺑѧﻴﻦ  79ﺷﻤﻠﺖ اﻟﺪراﺳﺔ 
% 6.68ﺷѧﻜﻠﺖ اﻟﻨѧﺴﺎء ﻓѧﻲ هѧﺬﻩ اﻟﺪراﺳѧﺔ . 27.41  +45.73 ﻋﺎﻣѧﺎ وﻣﺘﻮﺳѧﻂ اﻟﻌﻤѧﺮ هѧﻮ 04 و اﻗﻞ ﻣѧﻦ -03ﺷﻴﻮﻋﺎ هﻲ  
  . 5.6 : 1ﺑﻨﺴﺒﺔ ذآﻮر ﻟﻺﻧﺎث ﻗﺪرهﺎ  % 4.31وﺷﻜﻞ  اﻟﺬآﻮر 
ﺑѧﻴﻦ ﺗѧﻮرم اﻟﻐѧﺪة (    amoneda ralucillof)أﻇﻬﺮت اﻟﺪراﺳﺔ إن ﻧﺴﺒﺔ  ﺗﻔﺸﻲ اﻟﻮرم اﻟﺤﻤﻴѧﺪ اﻟﻤѧﺴﺎﻣﻲ 
  % .9.2وﻧﺴﺒﺔ ﺗﻔﺸﻲ اﻷورام اﻟﺨﺒﻴﺜﺔ  ،  % 5.7اﻟﺪرﻗﻴﺔ 
أﻇﻬѧѧﺮت اﻟﺪراﺳѧѧﺔ إن أآﺜѧѧﺮ أورام اﻟﻐѧѧﺪة اﻟﺪرﻗﻴѧѧﺔ ﺷѧѧﻴﻮﻋﺎ ﺑѧѧﻴﻦ اﻟﺠﻨѧѧﺴﻴﻦ هѧѧﻮ اﻟѧѧﻮرم اﻟﺤﻤﻴѧѧﺪ اﻟﻤѧѧﺴﺎﻣﻲ 
ﻣﻦ إﺟﻤﺎﻟﻲ أورام اﻟﻐﺪة اﻟﺪرﻗﻴﺔ ، وآѧﺎن أآﺜѧﺮ ﺷѧﻴﻮﻋﺎ ﻓѧﻲ اﻟﻔﺌѧﺔ اﻟﻌﻤﺮﻳѧﺔ  % 2.27 واﻟﺬي ﺷﻜﻞ amoneda ralucillof()
 وآﺎن أآﺜﺮ ﻣѧﺎ ﻳﻜѧﻮن 57.7 : 1وﻧﺴﺒﺔ اﻟﺬآﻮر ﻟﻺﻧﺎث  ﺳﻨﺔ  8.43  اﻷﻋﻤﺎروﻣﺘﻮﺳﻂ ( %6.87) ﻋﺎﻣﺎ 05 واﻗﻞ ﻣﻦ -02
  . ﻋﺎﻣﺎ 04 واﻗﻞ ﻣﻦ -03ﻓﻲ اﻟﻔﺌﺔ اﻟﻌﻤﺮﻳﺔ 
ﻣﻦ ﺟﻤﻠﺔ ﺗﻀﺨﻤﺎت اﻟﻐﺪة اﻟﺪرﻗﻴﺔ  وآﺎﻧﺖ هﺬﻩ اﻷورام اﻟﺨﺒﻴﺜﺔ  أآﺜﺮ  % 9.2ﺷﻜﻠﺖ اﻷورام اﻟﺨﺒﻴﺜﺔ ﻧﺴﺒﺔ 
وﻟﻢ ﺗﻈﻬѧﺮ أﻳѧﺔ ﺣﺎﻟѧﺔ ، % ( 5.55)آﺎﻧﺖ ﻧﺴﺒﺘﻪ ﻓﻲ هﺬﻩ اﻟﻔﺌﺔ   ﻋﺎﻣﺎ ﺣﻴﺚ 05 واﻗﻞ ﻣﻦ – 02ﺷﻴﻮﻋﺎ ﻓﻲ اﻟﻔﺌﺔ اﻟﻌﻤﺮﻳﺔ 
هﺬﻩ اﻟﻨﺘﺎﺋﺞ ﺗﻌﻨﻲ إن ﺳﺮﻃﺎﻧﺎت اﻟﻐﺪة اﻟﺪرﻗﻴﺔ ﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ أآﺜﺮ ﺷﻴﻮﻋﺎ ﺑѧﻴﻦ . ﺳﻨﺔ 11ورم ﺧﺒﻴﺚ ﻓﻲ ﻋﻤﺮ اﻗﻞ ﻣﻦ 
  . اﻟﺒﺎﻟﻐﻴﻦ وﻣﺘﻮﺳﻄﻲ اﻟﻌﻤﺮ  واﻗﻞ ﺷﻴﻮﻋﺎ ﺑﻴﻦ اﻷﻃﻔﺎل
 % 3.41ورم ﻏﻴѧѧﺮ ﻣﺤѧѧﺪد % 4.12 آﻠﻮﻳѧѧﺪي وآﺎﻧѧѧﺖ اﻟﻨﺘѧѧﺎﺋﺞ ورم % 3.41اﺳѧѧﺘﻌﻤﻞ اﻟﺮﺷѧѧﻒ ﺑѧѧﺎﻹﺑﺮ  ﺑﻨѧѧﺴﺒﻪ 
  %. 6.82ورم ﺣﻤﻴﺪ  % 4.12ورم ﺧﺒﻴﺚ % 3.41ﻣﺸﻜﻮك ﻓﻴﻪ 
أﻇﻬﺮت اﻟﺪراﺳﺔ إن ﺗﺴﺠﻴﻞ ﺑﻴﺎﻧﺎت اﻟﻤﺮﺿﻲ ﺿﻌﻴﻒ ﺟﺪا ﺧﺎﺻﺔ اﻟﺒﻴﺎﻧﺎت اﻟﻤﺘﻌﻠﻘѧﺔ ﺑﻌﻮاﻣѧﻞ اﻟﻤﺨѧﺎﻃﺮة ، 
  . اﻟﻌﺮﻗﻴﺔ ، ﻣﻤﺎ ﻳﺘﻄﻠﺐ ﻣﻌﺎﻟﺠﺔ ﺳﺮﻳﻌﺔ ﻟﻬﺬا اﻻﻣﺮأﺻﻞ اﻟﻤﺮض وأﺻﻮﻟﻬﻢ
ﺑﻜѧѧﻞ ﺟﻮاﻧﺒﻬѧѧﺎ ﻧﺠѧѧﺪ إن ﺗﻮزﻳѧѧﻊ أورام اﻟﻐѧѧﺪة اﻟﺪرﻗﻴѧѧﺔ ﺣѧѧﺴﺐ اﻷﻋﻤѧѧﺎر ، اﻟﺠѧѧﻨﺲ و إذا ﺗﺄﻣﻠﻨѧѧﺎ اﻟﺪراﺳѧѧﺔ هѧѧﺬﻩ 
 .  ﻓﻲ اﻟﺪول اﻻﺧﺮي اﻟﻤﺸﺎﺑﻬﺔ ﻧﺘﺎﺋﺞ اﻟﺪراﺳﺎت  وﻧﻤﻄﻬﺎ اﻟﻨﺴﻴﺠﻲ  ﻳﻤﺎﺛﻞ ﺗﻘﺮﻳﺒﺎ 
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CHAPTER ONE  
 
 
 
 
 
 
 
 
 
 
1-1 Introduction 
 
The estimated incidence of solitary palpable thyroid nodules in the 
adult population of the United States varies between 1% and 10%, 
although it is significantly higher in endemic goitrous regions. 
Single nodules are about four times more common in women than in 
men.The incidence of thyroid nodules increases throughout life. 
Fourtunately, the overwhelming majority of solitary nodules of the 
thyroid prove to be localized, non-neoplastic conditions, or benign 
neoplasm such as follicular adenomas. In fact, benign neoplasms 
outnumber thyroid carcinomas by a ratio of nearly 10: 1(1). 
Thyroid cancer accounts for approximately 1% of all malignancies 
in developed countries with an estimated annual incidence of 
122,000 cases worldwide. Benign throid tumors are common, and 
although cancers are relatively rare, they represent the most common 
malignancies of the endocrine system.The vast majority of 
carcinomas of follicular cell origin are indonlent maligancies with 10 
year survivals in excess of 90%. Thyroid cancer occurs primarily in 
young and middle aged adults and is rare in children. Numerous 
studies have demonestrated that thyroid cancer is two to four times 
more frequent in females than in males, but this sex difference is far 
less pronounced in children and older adults. Age standardized 
incidence rates per 100,000 populations in different parts of the 
world vary from 0.8 to 5.0 for males and 1.9 to 19.4 for females (2). 
Relatively low incidence rates of thyroid cancers have been reported 
in Denmark, the Netherlands and Slovakia while higher rates have 
been noted in Sweden,France, Japan and the United States(3). 
The overall incidence of thyroid cancer in the Middle East Cancer 
Consortium (MECC) countries from the period 1996 to 2001 was 
distributed across the international spectrum, with high rates for 
Israeli Jews and low rates for Egyptians. Only Icelanders had higher 
rates than Israeli Jews.Thyroid cancer contributed a small proportion 
of all cancers diagnosed annually in the MECC populations, ranging 
from 1.5% in Egyptians to 3.8% in Israeli Arabs, although the 
proportion was almost always higher than in the US SEER registries 
(1.7%). This pattern may be related to differences in the age 
structure of the populations. Although the burden of thyroid cancer 
relative to other malignancies was small in the MECC countries, 
there was considerable variation in incidence by age. In all Middle 
Eastern countries as well as the United States, patients aged 30- 49 
years at diagnosis contributed a substantial proportion of thyroid 
cancers, ranging from more than 30% to nearly 50% of all cases. 
Over 70% of thyroid cancers among female Cypriots, Israeli Arabs, 
and Jordanians occurred among patients younger than 50 years, 
compared with approximately 50% among female Israeli Jews and 
Egyptians. Likewise among males, patients younger than 50 years 
contributed approximately 70% of cases among Israeli Arabs and 
Jordanians. In Cypriots, Israeli Jews and Egyptians, from 40% to a 
little more than 50% of the cases in males occurred before age 50 
years. These distributions partly reflect the typical younger age at 
diagnosis of thyroid cancers compared with other cancers, but also 
the age structure of the underling population. Approximately 90% of 
Jordanians, Egyptians, and Israeli Arabs were younger than 50 years 
of age in 1996-2001. However the contribution of those under age 
50 years to the total thyroid cancers cases was lower for Egyptians 
compared with Jordanians and Israeli Arabs. Other case series have 
shown that thyroid cancer is, on average, diagnosed at a younger age 
in the Middle East compared with the average age of 45 years in the 
United States. The mean ages were 32 years in Israeli Arabs, 35 
years in Kuwaitis and 38 years in Yemenites. This variation in age at 
diagnosis could be entirely due to the much younger age structure of 
the populations in these countries, compared with the United States. 
Thyroid cancer age-standardized incidence rates (ASRs) among 
females were lowest in Bombay, India (2.0). Rates among females in 
MECC countries were intermediate –2.7 for Egyptians, 4.5 for 
Jordanians, 6.5 for Israeli Arabs, and 8.6 for Cypriots – except for 
the very high rates for Israeli Jews. In all countries, the  ASRs for 
females were at least twice as high as those for males, with ratios 
lower than 3  in Egypt and Jordan, and above 3  in Israel and Cyprus 
(4). 
The commonest tumors and their frequencies are, papillary 
carcinoma (70-80%), follicular carcinoma (10-20%), medullary 
carcinoma(5-10%), anaplastic carcinoma (2-10%), poorly 
differentiated carcinoma (0.4–10%), and malignant lymphoma(4-
5%). These percentages are expressed as the proportion of all thyroid 
malignancies(5). 
 
Thyroid tumors are treated primarily by surgery, but other adjuvant 
therapies are used after complete surgery has been done. The first 
surgery is the best time to do a complete surgery and decrease the 
number of complications.(6). 
 
The study showed the pattern of thyroid tumors in Sudan as 
reviewed in  National Health Laboratory, Radiation and Isotope 
Center-Khartoum and Soba University Hospital, with regard to age, 
sex, origin, risk factors and clinical presentation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 1-2 Literature Review 
 
1-2 -1 Normal Anatomy, embryology, histology 
and physiology: 
Anatomy: The thyroid gland consists of two symmetrical lobes 
united in the front of the second, third, and fourth tracheal rings by 
an isthmus of gland tissue.  
 
 
The gland possesses its own delicate histological capsule, or fascia 
propria.The isthmus joins the anterior surface of the lobes, towards 
their lower poles. Seperate masses of thyroid tissues are not 
uncommonly found near the hyoid bone, in the superior 
mediastinum, or beneath the sterno-mastoid muscle.The lymphatics 
follow the arteries. From the upper pole they enter the antero-
superior group of deep cervical lymph nodes. From the lower pole 
they pass with the inferior thyroid artery back to its point of origin 
from the subclavian artery behind the carotid sheath into postero-
inferior group. A few pass downwards into pretracheal  nodes, 
following the course of thyroid ima artery(7). 
 
Embryology: The thyroid gland is the first endocrine gland to 
develop in the embryo. It begins to form about 24 days after 
fertilization from a median endodermal thickening in the floor of 
primordial pharynx which soon form a small outpouching-the 
thyroid primordium- and divide into right and left lobes connected 
by the isthmus. The thyroid gland descends in the neck passing 
ventral to the developing hyoid bone and laryngeal cartilage. 
Histogenically, the thyroid primordium consist of a solid mass of 
endodermal cells. This cellular aggregate latter breaks up into a 
network of epithelial cords as it is invaded by the surrounding 
vascular mescenchyme. By the tenth week the cords have divided 
into small cellular groups. A lumen soon forms in each cell cluster 
and the cells become arranged in a single layer around a lumen. 
During the  eleventh week colloid begins to appear in these 
structures-throid follicles-there after iodine concentration and 
synthesis of thyroid hormones can be demonestrated(8). 
 
Histology: In the healthy adult, the thyroid weights 15-20 gms. It is 
enclosed by a thin collagenous capsule from which internal septa 
penetrate into the parenchyma, dividing it into irregular 
lobes(9).Thyroid tissue is composed of thousands of follicles that 
consist of spheres formed by simple epithelium whose lumen 
contains a gelatinous substance called colloid. In sections, follicular 
cells range from squamous to columnar and the follicles have an 
extremely variable diameter(10). Thyroglobulin is the storage form 
of thyroxine and is an iodinated glycoprotein.The size of an acinus 
depends on whether it is in a secretory or a storage phase(9). The 
cytoplasm of follicular cells  has a pale acidophilic or amphophilic 
staining quality, the greater the activity of the cell the greater its 
amount. Follicular cells with abundant granular acidophilic 
cytoplasm are referred to as HÜrthle cells, Ashanazy's cells, 
oxyphilic cells or oncocytes. Ultrastructurally, this granulity is due 
to accumulation of mitochondria.The intraluminal colloid is pale 
staining with scalloped borders in follicles with active secretory 
function and densely eosinophilic in inactive ones. Collection of 
small follicles protruding into the lumen of large follicles are 
commonly seen in actively secreting glands. They are sometimes 
referred to as Sanderson's polsters. The other major epithelial 
component of the thyroid gland is represented by neuroendocrine 
cells known as C cells or parafollicular cells. These cells are of 
presumed neural crest derivation and reach the thyroid via the 
ultimobranchial body(11).   
 
Physiology: The thyroid gland maintains the level of metabolism in 
the tissues that is optimal for their normal function. The thyroid 
gland is not essential for life, but in its absence there is mental and 
physical slowing, poor resistance to cold, and in children, mental 
retardation and dwarfism. Conversely, excess throid secretion leads 
to body waisting, nervousness, tachycardia tremor, and excess heat 
production. Thyroid function is controlled by thyroid stimulating 
hormne (TSH, thyrotropin) of the anterior pituitary. In mammals, the 
thyroid gland also secretes calcitonin, a calcium- lowering 
hormone(12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1-2-2 Epidemiology  
 
Thyroid cancer occurs primarily in young and middle aged adults 
and is rare in children.The mean age at diagnosis is the mid 40’s to 
early 50’s for the papillary type, 50’s for the follicular and medullary 
types and 60’s for the considerably less common poorly 
differentiated and undifferentiated types. Numerous studies have 
demonestrated that thyroid cancer is two to four times more frequent 
in females than in males, but this sex difference is far less 
pronounced in children and older adults. Age standardized incidence 
rates per 100,000 population in different parts of the world  vary 
from 0.8 to 5.0 for males and 1.9 to 19.4 for females.The lifetime 
risk of developing thyroid cancer in the United States is about 1:120 
for females while the risk of dying from the disease is approximately 
1in 1,700(2). 
Among United States  females, thyroid cancer accounts for about 3% 
of all cancers and is the eighth most common malignancy. In 
contrast, in Kuwait, thyroid cancer ranks second, comprising 8% of 
all female cancers, and similar findings have been reported for other 
countries in the Gulf region. Differentiated carcinoma (papillary and 
follicular subtypes) made up 90% to 94% of all thyroid cancers in 
Cypriots, Israel, Jordan, and the United States.The exception was 
Egypt, where only 73% of the thyroid cancers were differentiated. 
Some larger differences among countries emerged when more 
detailed histology was evaluated. Papillary carcinoma made up 80% 
or more of the thyroid cancers in Cypriots, Israeli Arabs and Jews, 
and the US population, whereas its contribution was considerably 
lower in Jordanians(77%), and Egyptians (62%). Medullary and 
anaplastic thyroid cancers were rare and contributed only 1% to 4%, 
except for Egypt, where 14% of all thyroid cancers were 
anaplastic.Earlier case series in Middle Eastern countries reported 
lower proportions of papillary carcinoma – e.g., 66% among Israeli 
Arabs in Northern Israel in the 1990s, and 58% in Kuwaitis in the 
1970s(4). 
 
 
 
1-2-3 Risk factors, etiology and pathogenesis  
Thyroid carcinomas can be caused by environmental, genetic and 
hormonal factors. Because of the thyroid’s dependence on 
environmental iodine, it is particular vulnerable to the genotoxic 
effects of radioactive iodine and to the nongenotoxic effects (TSH 
stimulation) resulting from iodine deficiency. In addition, thyroid 
tumours occur in the setting of several inherited cancer syndromes, 
including multiple endocrine  neoplasia(MEN) type2. Papillary 
thyroid carcinoma is most closely linked to radiation, either external 
radiation or internal irradiation from radioactive iodine. Young 
children are particularly susceptible. A striking increase in thyroid 
cancer in children has been reported in Belarus following the 
Chernobyl disaster of 1986. Because of its  ability to concentrate 
iodine, the thyroid dose from exposure to 1311 is, about 100 times 
greater than the rest of the body. Radiation is also a causative factor 
for follicular adenomas and carcinomas. Since radiation causes 
double strand breaks in DNA, a necessary precursor of RET and 
TRK rearrangements, this may be the reason why radiation is more 
closely associated with the development of papiIlary rather than 
follicular tumours.The etiology of follicular carcinoma is subject to 
the same influences described for papillary carcinoma, but with 
differing effects. Follicular carcinoma is particularly linked to 
dietary iodine deficiency. Iodine deficiency and genetic influences 
could account for its link with a history of nodular goiter. The 
relative frequency of papillary carcinoma is greater in geographic 
regions of adequate or high dietary iodine intake compared to 
regions of iodine deficiency. In regions of iodine deficiency, the 
relative frequency of papillary carcinoma increases after iodine 
supplementation, but it is not certain whether this is due to an 
absolute increase in the incidence of papillary carcinomas or a drop 
in the incidence of follicular carcinoma. Papillary carcinoma shows 
a significant association with lymphocytic thyroiditis, probably both 
as a result of the carcinoma provoking an autoimmune response and 
as a possible pathogenetic mechanism.  
The familial nature of medullary thyroid carcinoma(FMTC) is well 
known, with approximately 25% of cases belonging to one or other 
of the recognized syndromes of multiple endocrine neoplasia type 
2A (MEN 2A), MEN 2B, and familial medullary thyroid carcinoma 
(FMTC)(1).  
There is a strong, but as yet unexplained familial factor in the 
development of papillary thyroid carcinoma. RET and TRK 
rearrangements, which are characteristics of papillary carcinomas, 
are most likely related to double strand DNA breaks, often radiation 
induced. Recent studies have suggested that papillary carcinomas 
lacking these rearrangements may have BRAF mutations, which 
constitute a different route for tumorigenesis, or rearrangements in 
other genes involved in RET signaling pathways. Follicular 
neoplasms commonly demonstrate RAS mutations while follicular 
carcinomas and a minority of follicular adenomas exhibit 
PAX8/PPAR7 rearrangements. Germline mutations of RET, on the 
other hand, are responsible for the development of heritable 
medullary carcinomas while somatic mutations are involved in the 
development of a subset of sporadic medullary carcinomas. The 
RET mutations associated with medullary carcinomas are point 
mutations or small deletions in contrast to RET rearrangements 
found in papillary carcinoma.TP53 mutations are the most common 
molecular feature of undifferentiated thyroid carcinomas A subset of 
poorly differentiated and undiffrentiated carcinomas may also 
demonstrate BRAF mutations consistent with their origin from 
papillary carcinomas(2). 
  
 
 
 
 
 
 
 
 
 
1-2-4 Clinical course and diagnosis of thyroid tumors 
The clinical approach for thyroid tumors should start with proper 
history taking and clinical examination including past history of 
radiation exposure. For most thyroid tumors, diagnosis can be 
reached by morphologic assesssment alone. However, in tumors 
exhibiting unusual patterns or for confirming a diagnosis of 
medullary carcinoma, immunohistochemical studies are essential. 
The claimed utility of some antibodies or enzymes assay, such as 
HBME or dipeptidyl aminopeptidase 1V that can help to distinguish 
malignant thyroid neoplasms from benign thyroid lessions remain to 
be confirmed(5). 
Ultrasound is particularly useful for establishing the size of a lesion 
and its solid or cystic nature and also for guiding the performance of 
fine needle aspiration biopsies (FNAB). Neither CTs nor MRIs 
provide higher quality images of the thyroid than ultrasound; 
however, CTs of the lower cervical nodes are preferable to 
ultrasound when tracheal or mediastinal invasion is suspected. 
Nuclear scintigraphy(Tc99m) has been used extensively for the 
evaluation of nodular thyroid disease, particularly to determine 
whether the nodule is hot, warm or cold, but now used much less 
commonly because of the increased use of FNABs.  
Abnormalities in the levels of thyroid stimulating hormone(TSH) are 
rarely found in patients with thyroid malignancies although an 
elevated TSH may occur as a consequence of an associated 
thyroiditis. Low TSH levels, however, may indicate the presence of 
a hyperfunctioning(toxic) nodule.Thyroglobulin levels are not useful 
in the initial evaluation of patients with nodular thyroid disease, but 
useful in following the course of patients with recurrent and/or 
metastatic thyroid carcinom. Serum calcitonin levels is used 
routinely in the diagnosis and follow up of cases with medullary 
carcinoma, in patients with nodular thyroid disease, and a small but 
significant proportion of patients with elevations have had 
microscopic foci of medullary carcinoma or C-cell hyperplasia 
detected in the resected glands(2). 
FNAB is currently regarded as the test of choice for the diagnosis 
and management of thyroid nodules (36).With the advent of FNAB, 
the yield of thyroid cancer at surgery has increased from 15 to 40%. 
Results are generally classified as satisfactory or unsatisfactory(36). 
Those aspirates with insufficient cells are placed in the 
unsatisfactory category. Satisfactory smears are subdivided into 
benign, malignant and indeterminate/suspicious categories.The 
distinction between follicular adenomas and carcinomas cannot be 
made reliably on the basis of cytological examination, and for this 
reason, follicular neoplasms (including those of oncocytic 
type) are placed in the indeterminate/suspicious category. Other 
groups in the indeterminate/suspicious category include smears with 
features suggestive(but not diagnostic) of papillary and medullary 
carcinoma and cases of suspected lymphoma. Surgery is 
recommended for lesions classified as malignant or 
indeterminate/suspicious while those patients with benign smears are 
generally followed. Rebiopsy is recommended for patients with non-
diagnostic aspirates(13). 
Treatment: The treatment of most types of thyroid tumors is 
surgical. In cases in which the nodule is limited to one lobe, 
lobectomy(with or without isthmusectomy) is usually done as the 
first approach, with subsequent therapy depending on the nature of 
the nodule. Nodulectomy is no longer an accepted form of therapy 
for these lesions. Lobectomy is adequate therapy for follicular 
adenoma, including Hurthle cell adenoma. Subtotal thyroidectomy 
also constitute adequate therapy for most  minimally invasive 
follicular carcinomas(including minimally invasive Hurthle cell 
carcinomas), and papillary carcinomas. However the issue remain 
highly controversial, with several groups recommending total 
thyroidectomy followed by the administration of radioactive iodine. 
Total thyroidectomy should be reserved for the high- risk group of 
papillary carcinomas. Widely invasive follicular carciomas( 
including widely invasive Hurthle cell carcinomas), poorly 
differentiated carcinomas, and medullary carcinomas. Radical 
surgery should also be carried out in undifferentiated carcinoma 
whenever feasible. Suppresion of thyroid function is carried out 
routinely by the exogenous administration of thyroid hormones in 
cases of papillary and follicular carcinoma, although the need for 
this procedure has been questioned(11). 
Prognosis: In general terms the most important are the patient,s age( 
very significant), patient,s sex, tumor microscopic type, tumor 
microscopic grade and tumor stage(11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1-2-5 Classification of thyroid  tumours 
The traditional separation of thyroid carcinoma into the major 
groups of papillary, follicular, medullary and undifferentiated 
(anaplastic) carcinoma, based on morphology and clinical features, 
is strongly supported by advances in molecular studies showing the 
involvement of distinct genes in these four groups, with little 
overlap. However, some areas require further clarification.Other rare 
tumour types such as squamous and mucoepidermoid carcinomas 
cannot be regarded as subgroups of one of the major types, and are 
therefore treated separately. Poorly differentiated carcinomas may or 
may not show evidence of dedifferentiation from papillary or 
follicular carcinomas, and they are best treated as separate tumour 
types because of their clinical significance. Similarly, mixed 
medullary-follicular cell carcinomas remain of uncertain 
histogenesis and require separate classification.  
The oncocytic thyroid tumours pose a particular problem. 
Traditionally, they have been regarded as belonging to the ‘follicular 
family’ of thyroid neoplasms, they are classified as papillary 
carcinomas only if the nuclear features of that tumour type are 
present. No gene specific to oncocytic tumours has as yet been 
identified and sequenced, but it remains important to identify them 
separately for further molecular genetic studies.This general 
approach applies to all subtypes of thyroid carcinomas(2). 
 
 
 
 
 
 
 
 
 
WHO Histological classification of thyroid  tumours(1). 
Thyroid carcinomas    
Papillary carcinoma     
Folliocular carcinoma   
Poorly differentiated carcinoma       
Undifferentiated (anaplastic)  carcinoma                                       
Squamous cell carcinoma                 
Mucoepidermoid carcinoma             
Sclerosing mucoepidermoid  carcinoma with eosinophilia           
Mucinous carcinoma                         
Medullary carcinoma                        
Mixed medullary and follicularcell carcinoma  
Spindle cell tumor with thymus-like  differentiation  
Carcinoma showing thymus-like differentiation  
Thyroid adenoma and related tumors  
Follicular adenoma  
Hyalinizing trabecular tumor  
Other thyroid tumours 
Teratoma 
Primary lymphoma and plasmacytoma 
Thymoma 
Angiosarcoma 
Smooth muscle tumours 
Peripheral nerve sheath tumours 
Paraganglioma 
Solitary fibrous tumour 
Follicular dendritic cell tumour 
Langerhans cell histiocytosis 
Secondary tumours 
 
 
TNM classification of thyroid carcinomas(1).  
The TNM  system is endorsed by the International Union Against 
Cancer(UICC), and theAmerican Joint Commission on Cancer 
(AJCC). The recent TNM revision changed the definittion of T1 
from a tumour of 1cm or less in diameter to a tumour of 2cm or less, 
so that it is no longer consonant with the pathological definition of a 
microcarcinoma. Patients less than 45 years of age are classified as 
stageI if they have any T, any N, but no distant metastases (M0), 
while patients older than 45 years of age are classified as stages I to 
IV(2).  
 
T- primary tumor* 
TX  Primary tumor  cannot be assessed  
T0  No evidence of primary tumor  
T1  Tumor 2 cm or less in greatest dimension, limited to the thyroid  
T2  Tumor more than  2 cm but not more than 4 cm in greatest 
dimension limited to  thyroid  
T3  tumor more than 4 cm in greatest dimension, limited to the 
thyroid or any tumor with minimal extrathyrod extension (eg, 
extension to sternohyoid or perithyroid soft tissue)  
T4 a  tumor of any size extending beyond the thyroid capsule to 
invade subcutaneous soft  tissues , larynx, trachea, esophagus, or 
recurrent laryngeal nerve.  
T4b  tumor invades prevertebral fascia or encases carotid artery 
ormediastinal vessels 
*multifocal tumors are designated (m). The diameter of the largest determines the 
classification.  
All anaplastic (undifferentiated) tumours are considered T4  
T4a Intrathyroid anaplastic carcinoma- surgically resectable  
T4b Extra-thyroidal anaplastic carcinoma — surgically unresectable  
 
Regional Lymph Nodes (N)  
Regional nodes are the central compartment, lateral cervical and 
upper mediastinal lymph node.  
NX  Regional nodes cannot be assessed  
NO  No regional lymph node metastasis  
N1  Regional lymph node metastasis  
N1a  Metastasis to level VI (pretracheal, paratracheal, and 
prelaryngeal/Delphian) lymph nodes  
N1b  Metastasis to unilateral, bilateral or contralateral cervical or 
superior mediastnal lymph nodes 
Distant Metastasis (M)  
MX   Distant metastasis cannot be assessed  
MO   No distant metastasis  
Ml   Distant metastasis  
 
 
 
 
 
 
 
 
 
 
 
 
1-2-5-1  Follicular adenoma  
Defined as a benign, encapsulated tumour of the thyroid showing 
evidence of follicular cell differentiation. Follicular adenoma is  
difficult to analyse because of the lack of consistent criteria for 
distinguishing hyperplastic nodules and adenomas.The biological 
basis for separating nodules from adenomas is dependent on their 
clonality  and up to 60% of lesions in multinodular goiter have been 
shown to be monoclonal.The risk of progression to malignancy in 
males is relatively greater. Changing incidence of the occurrence of 
adenoma is related to changes in iodine intake, and in radiation 
exposure of differing populations(13). Follicular adenoma occurs 
mostly in adults aged 20-50 years, but no age group is exempted. Its 
more common in females. Male to female ratio is 1:6.Most patients 
present with a solitary thyroid nodule experienced for a variable 
periods. The adenomas usually lack intake on iodine scan(cold 
nodule), but rare ones may be "hot"" and can cause 
hyperthyroidism(so-called toxic adenoma). Follicular adenoma are 
totally benign and are adequately treated by lobectomy(5).  
The association with radiation is better documented than that for 
follicular carcinoma, and radiation induced adenomas show a very 
long mean latent period. Adenomas are common in iodine deficient 
areas, usually as part of a nodular goiter(13).  
 
Diagnosis: Follicular adenomas are frequently discovered by 
ultrasound. Radioactive iodine scans generally show hypofunction, 
while ultrasound demonstrates a solitary solid nodule. A minority of 
adenomas are “hot” on scan and are associated with 
hyperthyroidism(13). 
Macroscopy: Follicular adenoma is usually a solitary round or oval, 
nodule(usually1-3cm) surrounded by a thin capsule.The cut surfaces 
show grey-white, tan or brown fleshy tumour. Secondary changes 
such as haemorrhage and cytic degeneration may be present. 
Occasionally, follicular adenomas can arise in a background of 
nodular hyperplasia, and the tumour is distinguishable from the 
background nodules (colloid or hyperplastic) by th encapsulation 
and the fleshy appearance.  
Cytopathology: Aspirates of follicular adenorna are usually cellular 
with numerous follicular cells and little or no colloid. Most often, 
the follicular cells exhibit a microfollicular pattern which consists of 
groups of 6-12 nuclei in a small ring sometimes with a central dot of 
colloid. Macrofollicular adenomas demonstrate abundant colloid 
with follicular cells arranged in monolayer sheets. This appearance 
is very similar to that observed in adenomatoid nodules. The 
distinction of follicular adenomas and carcinomas is not possible in 
cytologic preparations.  
Histopathology: Follicular adenoma is typically enclosed in a fibrous 
capsule of variable thickness. By definition, capsular or vascular 
invasion are absent.The tumor can show a variety of architectural 
features, most commonly follicular  or trabecular. The tumour cells 
are cuboidal, columnar or polygonal, and often have uniform, dark, 
round nuclei, although occasional enlarged hyperchromatic nuclei 
can be present. Mitotic figures are rare. There is usually only scanty 
stroma, which is richly vascularized by delicate capillaries that may 
not be obvious in conventional histologic sections. Secondary 
changes such as stromal oedema, fibrosis, hyalinization, 
haemorrhage, calcification, cartilaginous metaplasia, cyst formation, 
and infarction can supervene. The growth pattern may be 
“normofollicular”, “macrofollicular” and “microfollicular”,or a 
single tumour may show more than one of these architectural 
patterns. Rarely, papillae can be present focally(14). 
Immunohistochemistry: The enzyme histochemical, and  
immunohistochemical profile of adenomas mirrors that of the 
normal follicle.There is reactivity for low-molecular-weight keratin 
and thyroglobulin in the cytoplasm and for laminin and other 
basement membrane components around the follicles. Follicular 
adenomas are immunoreactive for cytokeratins, thyroglobulin and 
TTF1, but not CK 19, calcitonin or panneuroendocrine markers(11).  
The differential diagnosis between a dominant nodule from a case of 
nodular hyperplasia and a true adenoma is based on a set of 
admittedly arbitrary criteria. The adenoma is usually single, is totally 
surrounded by a capsule, is dissimilar  from the remaining 
paranchyma, compresses the adjacent tissue, and is composed 
mainly of follicles that are smaller than those of the normal 
gland.The lession of nodular hyperplasia is almost always one of 
many nodules, its encapsulation is incomplete, the follicular size is 
variable, some or all of the follicles are larger than those in the 
surrounding gland and there is no compression of the adjacent 
paranchyma. In some cases, the distinction becomes impossible, in 
as much as lesions with the morphologic features of adenoma may 
be multiple and/or occur in a setting of nodular hyperplasia(11).      
Variants  
Oncocytic adenoma; is characterized by a distinct mahogany 
brown appearance, often with central areas of scarring. The tumours 
are composed of cells with abundant granular eosinophilic 
cytoplasm and large open nuclei with prominent nucleoli. It has a 
variety of architectural patterns ranging from well formed follicles to 
solid and/or trabecular growth(14). 
Other variants: Follicular adenoma with papillary hyperplasia  
is usually encapsulated and partially cystic. It comprises broad or 
delicate branching papillae as well as follicles, lined by columnar 
cells with uniform, round and hyperchromatic nuclei. This tumour 
occurs predominantly in children and adolescents and may he 
multiple.  
Toxic(hyperfunctioning) adenoma is a follicular adenoma associated 
with symptoms of hyperthyroidism due to autonomous production of 
thyroxine. Histologically, the follicles are lined by tall cells, often 
showing papillary projections within the lumina, similar to the 
follicles seen in Graves disease. The tumour appears as a “hot” 
nodule on radioactive iodine scan. Atypical adenoma is a  
follicular neoplasms exhibiting high cellularity, nuclear atypia, or 
unusual histologic patterns (such as spindle cell fascicles), but 
lacking vascular and capsular invasion on thorough sampling, this 
tumour pursues a benign course. Use of this term is discouraged. 
Follicular adenoma with bizarre nuclei is a variant characterized by 
the presence of isolated or small groups of monstrous tumour cells 
with enlarged hyperchromatic nuclei within an otherwise typical 
follicular adenoma(14). 
Treatment :  The standard therapy for follicular adenoma is 
removal by lobectomy.Enucleation of the adenoma should not be 
attempted. Suppression of the nodule with levothyroxine and 
treatment of the toxic adenoma with 131 I have been used, but the 
results have generally been less than satisfactory(11).     
 
Prognostic and predictive factors  
Provided the adenoma is completely removed there is no further 
risk(14).  
 
Hyalinizing trabecular tumour(HTA): HTA is the term given 
to a peculiar type of adenoma exhibiting a prominent trabecular 
arrangement and an equally prominent hyaline appearance. 
Considerable controversy has arisen as to whether HTA is a distinct 
entity or a pattern of growth that can be present in a variety of 
thyroid lesions, the latter being the view currently favored. Even 
more controversial and intriguing is the apparent pathogenetic link 
between HTA and papillary carcinoma. It has been suggested that 
HTA is yet another morphologic variant of papillary 
carcinoma((11).The tumor is unusual under the age of 30 years and 
is about equally distributed in the fourth through the seven decades 
with a mean age of 47 years. There is a marked female predeliction. 
HTA is a solid epithelial neoplasm that is circumscribed and 
may be surrounded by a thin capsule.It features a trabecular-
alveolar growth pattern of medium to large size cells with finely 
granular, acidophilic, amorphic or clear cytoplasm, 
intratrabecular hyaline (PAS-positive basement membrane 
material), polgonal and fusiform cells, nuclei with prominent 
grooves and cytoplasmic pseudoinclusions, and small nucleoli. 
Psammoma  bodies may be present. The PAS-positive hyaline 
material resemble amyloid but amyloid stains are negative. The 
recognition of RET/PTC rearrangement in some of the tumors 
suggest a relationship with papillary thyroid carcinoma(15). 
 
 
 
 
 
1-2-5-2  Papillary carcinoma(Papillary adenocarcinoma; 
mixed papilIary and follicular adenocarcinoma).  
Defined as a malignant epithelial tumor showing evidence of  
follicular cell differentiation and characterized by distinctive nuclear 
features. Papillary carcinoma is rare before the age of 15 years. 
They represent the most common paediatric thyroid malignancy. 
Most tumours manifest in adult of 20-50 years, with a female to 
male ratio of 4:1. Female predominance is less pronounced over the 
age of 50 (16). Fletcher(5) reported that follicular carcinoma occur 
in a wide age range with a mean of 43 years and male to female ratio 
of 1:2.5. It  is the most common malignant tumor of the gland in 
countries having iodine- sufficient or iodine excess diets, and 
comprises about 80% of thyroid malignancies in the United 
States(17). 
Most patients present with a painless thyroid or neck mass. However 
some present initially with lymph node metastasis, and the occult 
primary tumor in the thyroid is almost always found on the 
ipsilateral side(5). Extrathyroidal extension into the soft tissues of 
the neck is found in about one fourth of cases, and it may extend to 
parathyroid gland. Involvement of cervical lymph nodes is very 
common(particularly in young patients), and it may be the first 
manifestation of the disease(11).  
Overall survival is excellent (greater than 90%) particularly for 
patients younger than 45 years.The incidence of papillary carcinoma 
has increased worldwide, but the mortality rate is declining. The 
prevalence of papillary carcinoma varies between 5-35%  and this 
variation is heavily dependent on the sampling technique(16). Most 
tumors are diagnosed in patients in the third and fifth decades(18). 
The etiology of papillary thyroid carcinoma is most closely linked to 
radiation exposure. There is no known precursor lesion of papillary 
thyroid carcinoma.The cell of origin of papillary carcinoma is 
the follicular cell(16). 
The cardinal molecular alteration in papillary thyroid carcinoma is 
an alteration of RET.This is a proto-oncogene located on 
chromosome 10q11.2 that encodes a transmembrane receptor with 
tyrosine kinase activity.This  alteration is not a germline point 
mutation, but one or another of several somatic rearrangements, the 
most important of which are designated as RET/PTC3 and 
RET/PTC2(listed in order of decreasing frequency). It has been 
claimed that this aberration is specific for the papillary carcinoma 
histotype. Other genetic alterations found in papillary carcinoma involve 
the gene NTRK1, point mutation in ras and lack of expression of the Rb 
gene(11). 
Diagnosis: Usually presents as a thyroid mass which is typically 
cold on radioactive iodine scan or as cervical lymphadenopathy(25% 
of young patients). FNAB is an effective method of diagnosing 
papillary carcinoma(13). Papillary carcinoma shows a variety of 
gross patterns. Most lesions are grey-white firm masses with 
irregular borders or even gross infiltration of the surrounding thyroid 
parenchyma. Some show dystrophic calcification and occasionally 
demonstrate bone formation. The size ranges from minute(<1mm) to 
several centimeters and multicentricity is common. Many tumours 
will show cystic changes and rarely the tumor is almost entirely 
cystic. Aspirates from conventional papillary carcinomas typically 
contain abundant cells that may be grouped in papillary tissue 
fragments, monolayered sheets and three dimensional clusters. The 
characteristic nuclear features of papillary carcinoma include 
enlargement, oval shape, elongation, and overlapping.The nuclei 
typically show clearing, or a ground glass appearance. Irregularity of 
nuclear contours including grooves and nuclear pseudoinclusions, 
are common. In tumours without complex papillary structures, the 
diagnosis of papillary carcinoma relies on these nuclear features, 
which should be present in a significant proportion of the 
neoplasm.Psammoma bodies are seen in approximately half of the 
cases.Their presence strongly suggests the diagnosis of papillary 
carcinoma, inasmuch as their occurrence in other thyroid lesions is 
exceptional. Psammoma bodies are also seen in frozen section and if 
enough roentgenograms. If they are present in what is otherwise 
normal thyroid tissue or lymph nodes from the neck, the chances are 
high that a papillary carcinoma is present in the immediate 
vicinity(18). 
Histochemical and immunohistochemical features: the cells of 
papillary carcinoma are reactive for pan-keratin stains. Their usual 
profile is CK7+/CK20. Of potentially greater diagnostic importance 
is the fact that the cells of this tumor stain for cytokeratin 19 and for 
the high-molecular-weight keratin, thyroglobulin and thyroid 
transcription factor1(TTF-1), but are negative for synaptophysin and 
chromogranin. A number of immunohistochemical  markers have 
been proposed to confirm diagnosis of papillary carcinoma. 
Candidate marker include S100 protein, HLA-DR, estrogen receptor, 
high molecular weight cytokeratins(CK), CK19 and RET. Other 
suggested markers of malignancy in papillary lesions include 
HBME1 and galectin-3, but neither is specific for these tumours. 
CK19 has been widely applied as a marker for papillary carcinoma 
but also remains controversial since it is also positive in chronic 
lymphocytic thyroiditis and at sites of reaction, usually in response 
to previous aspiration biopsy(11).  
The use of RET staining to identify expression of a RET/PTC 
rearrangement is dependent on the availability of reliable and 
sensitive/antibodies.Tumors with metastasis typically show loss of 
p27 or up regulation of cyclin D1, while non-metastatic papillary 
carcinomas are positive for p27 and negative for cyclin D1. 
Metastasis of papillary carcinoma of thyroid origin are positive for 
TTF-1 and thyroglobulin. Papillary carcinoma from sites other than 
the lung and thyroid are typically negative for both TTF-1 and 
thyroglobulin(in the case of TTF-1, shared with the pulmonary 
epithelium)(16). 
Electron microscopic features: ultrastructurally, the most distinctive 
feature of cells of papillary carcinoma is the highly indented  nuclear 
membrane, with formation of pseudoinclusions and multilobulation 
(11). 
 
Variants of papillary carcinoma 
Papillary microcarcinomas 
This is defined as a papillary carcinoma measuring 1 cm or less in 
diameter. Most cases have stellate configuration and correspond to the 
lesions formerly known as occult sclerosing carcinoma or 
nonencapsulated sclerosing tumors, whereas others show partial or near 
total encapsulation, with or without tumor outside the capsule. It,s 
microscopic features and the loss of heterozygosity (LOH) mutational 
profile so far investigated are not different from those of their large 
counterpart. Papillary microcarcinoma is an extremely common 
incidental finding(25% or more, depending on the throughness of the 
examination) in the thyroid glands removed for other reasons and in 
population-based autopsy studies. In contrast to it,s clinically evident 
counterpart, papillary microcarcinoma seems to be more common in 
males than females. It may be associated with cervical node metastases, 
but distant  metastases are exceptionally rare.  It is the most common 
form of papillary carcinoma, the survival rates indistinguishable from 
those of the normal population (11,19). Fletcher (5) reported that 
papillary microcarcinoma has been reported to show highly variable 
prevalence rate in different countries. The highest rate has been reported 
in Finland(36.6%) and the lowest in Switzerland(1.2%). Sources of these 
differences have attributed these findings to differences in diagnostic 
criteria and techniques of examination, but a genetic factor is probably 
also responsible(5).   
 
Other variants 
Follicular variant: Grossly, many of these tumours resemble 
encapsulated follicular neoplasms.The majority of cells lining the 
follicles contain large clear nuclei with grooves and nuclear 
pseudoinclusion. Intrafollicular multinucleate giant cells may be 
frequent in this variant, while stromal sclerosis and psammoma 
bodies are seen occasionally.  
Macrofollicular  variant:This is probably the rarest form. It is 
composed predominantly or exclusively of macrofollicles (>50 % of 
a cross sectional area) and, most of the tumors are encapsulated. 
However, some follicles are lined by cells with large clear nuclei 
with grooves and pseudoinclusions charactarestic of papillary 
carcinoma. This variant is chareacterized by a low incidence of 
lymph node  metastasis. 
 
Oncocytic variant: Charecterized grossly by a distinct mahogany 
brown appearance and may have papillary or follicular architecture, 
occasional may appear grey-white.The diagnosis is based on the 
nuclear features of these lesions which are identical to those seen in 
papillary carcinoma of conventional type(15,19). 
Clear cell variant: Both conventional papillary carcinomas and the 
follicular variants may be composed predominantly of clear cells. 
Often a papillary architecture predominates but some may have a 
follicular or admixture of oncocytic and clear cells. The nuclear 
features are those of conventional papillary carcinoma. 
Diffuse sclerosing variant: Tends to occur in young patients and is 
characterized by diffuse involvement of one or both thyroid lobes, 
usually without forming a dominant mass. They are characterized by 
extensive squamous metaplasia, numerous psammoma bodies, dense 
lymphocytic infiltration and stromal fibrosis.  
Tall cell variant: Is rare, composed predominantly of cells whose 
heights are at least three times their width. The neoplastic cells have 
abundant eosinophilic cytoplasm and nuclei similar to those of 
conventional papillary carcinoma. These tumours occur in older 
patients, often males, and tend to show a more aggressive clinical 
behavior than usual papillay carcinoma(15,19). 
Combined papillary and medullary carcinoma  
The papillary carcinoma usually represent a minor component 
(<25%) of the tumor. Each component can be identified  by its 
nuclear features. Both components are positive for TTF1(16).  
Prognosis is excellent, 10-year survival is over 90% and for young 
patients is over 98%. The relative proportion of papillary and 
follicular areas does not correlate with prognosis but vascular 
invasion and nuclear atypia may be adverse prognostic signs{16). 
 
 
 
 
1-2-5-3 Follicular carcinoma(Follicular 
adenocarcinoma;oncocytic carcinoma; HÜrthle cell carcinoma).  
Defined as a malignant epithelial tumour showing evidence of 
follicular cell differentiation and lacking the diagnostic nuclear 
features of papillary carcinoma. Follicular carcinoma accounts 
for 10-15% of clinically evident thyroid malignancies. It is more 
common in women and tends to occur in patients in the fifth 
decade.The peak incidence of oncocytic follicular carcinoma is 
approximately 10 years later than follicular carcinomas of 
conventional type. At variance with papillary carcinoma, follicular 
carcinoma rarely occurs in children. A single case of a follicular 
carcinoma in a newborn has been reported to date. The incidence of 
follicular carcinoma is higher in iodine-deficient areas. Dietary 
iodine supplementation has been associated with an increase in the 
relative frequency of papillary carcinoma and a decrease in the 
relative frequency of follicular carcinoma. The frequency of 
follicular carcinoma has also decreased recently, due to the 
exclusion from this category of the follicular variant of papillary 
carcinoma. Both iodine deficiency and irradiation have been 
implicated in the development of follicular carcinoma, as discussed 
in the introduction. No definite precursor lesions are known.The cell 
of origin is the follicular epithelial cell (20). Allelic imbalance, 
comparative genomic hybridization, and cytogenetic studies have 
suggested involvement of chromosomes 2 in follicular 
carcinomas(11). Oncocytic neoplasms show frequent chromosomal 
DNA imbalance, with numerical chromosomal alterations being the 
dominant feature(21). Somatic mutations and sequence variants of 
mitochondrial DNA (mt DNA) have been identified in oncocytic 
thyroid carcinomas. Similar changes have been found in the non-
tumourous thyroid tissue of patients with oncocytic neoplasms(21), 
suggesting that certain polymorphisms predispose to this cytologic 
alteration. Mutations of the RAS genes are found  in  20-50% of 
follicular carciomas(11).  
Diagnosis: Follicular carcinoma most commonly presents as a mass 
lesion and is often larger than papillary carcinomas at presentation. 
The frequency of ipsilateral lymphadenopathy is considerably less 
than that observed in patients with papillary carcinoma (less than 5% 
in most series). Hoarseness dysphagia and dyspnea are rare at 
presentation. Distant metastases have been reported in up to 20% of 
patients at presentation with the most common sites of involvement 
being lungs and bone. Oncocytic follicullar carcinomas have a 
similar clinical presentation. A somewhat higher proportion of 
patients with these tumours have ipsilateral nodal involvement.The 
cumulative incidence of metastases was somewhat higher in 
oncocytic (33%) than in non-oncocytic (22%) follicular 
carcinomas(20). 
Macroscopically follicular carcinomas are usually encapsulated 
round to ovoid solid tumours generally measuring more than 1cm in 
diameter. On cross section, they have bulging surfaces and vary in 
color from gray-tan to brown. Follicular carcinomas tend to have 
thicker and more irregular capsules than follicular adenoma. In some 
instances, however, widely invasive tumours may lack any evidence 
of encapsulation.  
Aspirates from follicular carcinoma are generally hypercellular with 
a dispersed follicular arrangement of tumour cells and scanty 
colloid. The diagnosis of malignancy depends on the demonstration 
of capsular or vascular invasion which is demonstrable only in 
histological preparations (20). 
Histopathology: The microscopic appearance of follicular carcinoma 
is extremely variable, ranging from well formed colloid-containing 
follicles to solid or trabecular growth patterns. Poorly formed 
follicles or atypical patterns (eg cribriform) may occur and 
coexistence of multiple architectural types is common. However, 
neither architectural nor cytological atypical features, by themselves, 
are reliable criteria of malignancy since these changes may be 
present in benign lesions, including nodular (adenomatous) goiters 
and adenomas(11). Follicular carcinomas of either subtype are 
almost always solitary and practically never occult. Metastases are 
usually blood-borne rather than to regional nodes.These metastasis 
may exhibit a better differentiated appearance than the primary 
tumor, to the point of looking like normal thyroid(so-called 
“metastasizing adenoma,” “malignant adenoma,” or “metastasizing 
goiter”).These metastases are common in the widely invasive type, 
occur in fewer than 5% of the minimally invasive tumors with blood 
vessel invasion, and develop in fewer than 1% of the tumors 
diagnosed as carcinoma only on the basis of minimal capsular 
invasion(11).  
The prognosis of follicular carcinoma is directly related to the 
degree of encapsulation, hence the important distinction between 
minimally invasive and widely invasive follicular carcinomas(20). 
Immunohistochemically, follicular carcinomas are reactive for 
thyroglobulin,TTF-l, low-molecular-weight keratin, EMA, and 
basement membrane components such as laminin and type IV   
collagen. Their reactivity for these and other markers is not 
significantly different from that of follicular adenomas. This also 
applies to their lectin-binding pattern and ultrastructural 
appearance(11).  
Invasiveness  
Classically, follicular carcinomas have been divided according to 
their degree of invasiveness into two major categories. Minimally 
invasive follicular carcinomas have limitted capsular and/or vascular 
invasion. Widely invasive follicular carcinomas have widespread 
infiltration of adjacent thyroid tissue and/or blood vessels(11).    
Minimally invasive: Have limited capsular and/or vascular 
invasion. It is grossly an encapsulated tumor, often with a solid and 
fleshy cut surface.The pattern of growth usually resembles that of an 
adenoma of embryonal, fetal, or atypical type. A mimic of vascular 
invasion is represented by the sometimes extremely florid 
proliferation of endothelial and smooth muscle cells of capsular 
vessels, which may even acquire a Kaposi’s-like appearance; this 
peculiar change can also be seen in follicular adenomas, but with a 
much lower frequency. Search for endothelial markers is more 
rewarding. Interruption of the capsule must be full thickness for the 
process to qualify as capsular invasion. Foci of capsular invasion 
should be distinguished from capsular rupture resulting from a fine 
needle aspiration procedure. Another mimic is represented by the 
pseudoinvasion resulting from herniation of tumor tissue when the 
section for histology has been taken perpendicularly to a previous 
capsule cut made by the surgeon or pathologist on the fresh 
specimen. Evans(11) has made the interesting observation, 
confirmed by others that the capsule of follicular carcinoma tends to 
be thicker and more irregular than that of adenoma(22).  
 
Terminology:  
The following terminology were recommended by a  group of 
thyroid pathologists(11). 
• For tumors showing definite capsular invasion: follicular 
carcinoma  
• For tumors showing questionable capsular invasion:  
follicular tumor of uncertain malignant potential (FT-
UMP) if papillary carcinoma-type nuclear changes are absent, 
and well-differentiated tumor of uncertain malignant 
potential (WDT-UMP) if those nuclear changes are 
questionable.  
Widely invasive follicular carcinoma is the high-risk counterpart of 
the minimally invasive subtype. It shows widespread infiltration of 
blood vessels (4 vessels or more) and/or adjacent thyroid tissue. It 
often lacks encapsulation altogether(11). 
Histopathological variants 
Oncocytic variant(oxyphilic and Hurthle cell carcinoma.)  
Oncocytic follicular carcinomas are composed exclusively or 
predominantly (greater than 75%) of oncocytic cells. It represents 3-
4% of thyroid malignancies. The median age at diagnosis is 61 years 
and the female to male ratio is 6.5 : 3.5. There is no evidence at 
present to suggest that the etiology of the oncocytic follicular 
carcinomas differs from that of follicular carcinomas of conventional 
type although some studies have suggested a primary role of 
mitochondrial abnormalities in the genesis of these tumours.The 
oncocytic variants are associated with nodal metastases in 
approximately 30% of cases( follicular carcinomas of conventional 
type  in less than 5% of cases). Architectural patterns ranging from 
well formed follicles to solid and/or trabecular growth patterns. 
Clear cell variant may be composed predominantly of clear cells that 
contain glycogen, mucin, lipid or dilated mitochondria. Signet-ring 
follicular cells can also be a minor or a major component of
 follicular carcinomas(20). 
Prognosis and predictive factors  
 In general, minimally invasive follicular carcinomas have a very 
low long term mortality in the range of 3 to 5% with survival curves 
approaching those of a normal population matched for age and sex. 
Widely invasive carcinomas have a long term mortality of 
approximately 50%. These generalizations apply both to 
conventional follicular carcinomas and follicular carcinomas of 
oncocytic type. Generally, oncocytic carcinomas behave more 
aggressively than follicular carcinomas of conventional type, with 
higher frequencies of extrathyroidal invasion, local recurrence and 
nodal metastases((23). 
Risk group analysis for follicular carcinomas. From Shah et al (20).  
Factor  Low  Intermediate  Intermediate  High  
Age (yrs)  <45  >45  ≥45  ≥45  
T  T1/T2  T3/T4 and/or  Tl/T2  T3/T4 and/or T1/T2  
M  M0  Ml and/or  M0 Ml and/or M0  
Type  Non-oncocytic  
Oncocytic 
and/or  Non-oncocytic 
Oncocytic and/or 
non-oncocytic  
Grade  Low  High  Low  High  
The results of earlier studies had suggested that all oncocytic tumors 
were potentially malignant; however, more recent studies have 
shown that histologic features, simillar to those used for 
conventional follicular carcinomas, can be used to predict biologic 
behaviour(11).  
  
1-2-5-4 Poorly differentiated carcinoma  
Defined as a follicular cell neoplasm that show limited evidence of 
structural follicular cell differentiation and occupy both 
morphogically and behaviourally an intermediate position between 
differentiated (follicular and papillary carcinomas) and 
undifterentiated anaplastic carcinomas. Poorly differentiated 
carcinoma remains a controversial entity. It is therefore difficult to 
evaluate whether the different prevalence rates among different 
geographic regions reflect true etiological differences or mere 
variations in diagnostic criteria. For example, this etitity accounts for 
4-7% of all the clinically evident thyroid carcinomas in Italy and in 
some Latin American countries; compared to much lower rates in 
United States.The disease is more common in women and in 
patients older than 50 years. The etiology is unknown. While some 
of these tumours appear to arise from preexisting papillary and 
follicular thyroid carcinomas, others most likely arise
 denovo{(24).  
The lesions are often large, gray-white in color, infiltrative and show 
extensive necrosis. Microscopically the tumor is composed of small 
nests of cells, which have a neuroendocrine growth pattern. 
Necrosis, vascular invasion and mitosis are prominent features.The 
tumor cells should stay positive for thyroglobulin and negative for 
calcitonin(18).    
The proportion of unbalanced DNA profiles in poorly differentiated 
thyroid cancer is 80%, similar to that detected in undifferentiated 
thyroid carcinoma, with a median number of chromosome gains or 
losses (5.5 per case). Specific types of chromosomal alteration  such 
as +1p34-36, +17q25. +0q, +20q, -1p11-31,-6q21,-13q21-31 are 
assciated with the transition from well differntiated carcinomas to 
poorly differentiatd carcinomas. Poorly diffrentiated thyroid 
carcinomas have a frequency of genetic alterations intermediate 
between well-differentiated and undifferentiated carcinomas. 
Analysis of TP53 exons 5-9 shows mutations in 20-30% of poorly 
differentiated carcinomas. Aberrant TP53 immunoreactivity is 
detectable in 40-50% of poorly differentiated carcinomas, a 
prevalence that is not very different from that observed in 
undifferentiated carcinomas (50-80%). The mean five-year survival 
rate is about 50% in most series. The majority of patients die in the 
first three years after diagnosis and few patients survive >5 
years(24).  
 
 
 
 
1-2-5-5 Undifferentiated(anaplastic)carcinoma 
(UTC)(Spindle and giant cell carcinoma, sarcomatoid carcinoma, 
pleomorphic carcinoma, dedifferentiated carcinoma, metaplastic 
carcinoma, carcinosarcoma) 
UTC are highly malignant tumours that histologically appear wholly 
or partially composed of undifferentiated cells that exhibit 
immunohistochemical or ultra-structural features indicative of 
epithelial differentiation. UTC occurs mainly in the elderly, with a 
female to male ratio of 1.5:1. The incidence is approximately 
one or two cases/million annually, but this varies geographically, 
with a higher incidence in Europe than in the USA. A higher 
incidence has also been reported in endemic goiter regions. UTC 
accounts for less than 5% of clinically recognized malignant thyroid 
necplasms. Mortality rate is over 90%, with a mean survival of 6 
months after diagnosis. Most cases of UTC show evidence of a pre-
existing differentiated or poorly differentiated thyroid carcinoma. 
UTC is characterized by complex chromosomal alterations.The most 
consistent finding is the strong association of UTC with TP53 
mutations(25). 
Anaplastic carcinoma may account for up to 30-40% in places where 
goitre is endemic. It occurs more commonly in females ( male 
/female ratio is 1: 1.1 to 1:1.4) and older subjects, with a mean age 
of 66.6 years(5).      
  
Diagnosis: Usually presents in elderly patients as a rapidly growing 
mass associated with hoarseness, dysphagia, and dyspnea. 
Extrathyroidal extension is encountered at the time of initial 
presentation in most of the cases. Surrounding 
structures are frequently invaded. Cardiac metastases have also been 
described.  
Macroscopically the tumours are large, fleshy, and white-tan in 
colour, often exhibiting areas of necrosis and haemorrhage. They are 
typically infiltrative with invasion into the surrounding soft tissue. 
Aspirates are typically highly cellular. The cells are present singly or 
in clusters and there is marked nuclear pleomorphism.The cell types 
include squamoid, giant cell and spindle cell. The nuclei are bizarre 
and single or multiple. They reveal coarsely clumped chromatin and 
single or multiple prominent nucleoli. Mitotic figures may be 
numerous. The smear background reveals necrotic debris often with 
accompanying polymorphonuclear leukocytes. The majority of 
UTCs are widely invasive tumours composed of an admixture of 
spindle cells, pleomorphic giant cells and epithelioid cells. There is 
considerable variation in both the percentage and distribution of 
these cellular elements from case to case. In most cases, mitotic 
figures are a frequent finding. Extensive coagulative necrosis with 
irregular borders and palisading is often seen. Infiltration of vascular 
walls often accompanied by obliteration of the vascular lumina is 
common. Occasional osteoclast-like giant cells are common(25). 
Electron microscopic and immunohistologic studies have indicated 
that almost all anaplastic thyroid tumors are indeed epithelial in 
nature. The cells contain many cytoplasmic organells and dense 
bodies similar to those found in follicular epithelium. By 
immunohistochemistry, anaplastic thyroid carcinomas should be 
positive for cytokeratin.Thyroglobulin immunostaining is often 
negative(18).When an UTC is well sampled, it is possible to find 
well differentiated or poorly differentiated thyroid carcinoma, in a 
significant proportion of the cases. This finding supports the belief  
that UTC arises from the transformation(dedifferentiation) of a pre-
existing better differentiated carcinoma. Some cases  may,
 however, arise denovo. Current vidence indicates that 
undifferentiated thyroid carcinomas originate  from follicular 
cells.Undifferentiated carcinomas typically spread beyond the 
thyroid by direct local extension. Metastases to regional nodes are 
also common. Distant metastases may be present in any site. All 
undifferentiated carcinomas are considered to be grade T4 
tumours.UTC is a highly aggressive malignant neoplasm typified by 
rapidly progressive local disease. The overall five year survival 
ranges from 0-14%, and the median survival is 2.5-6 months. 
Prognostic factors are related primarily to the extent of disease at 
presentation(25).  
 
 
 
1-2-5-6 Squamous cell carcinoma (Epidermoid 
carcinoma)  
Squamous cell carcinoma of the thyroid is a malignant epithelial 
tumour composed entirely of cells with squamous cell 
differentiation.These tumours account for up to 1% of thyroid 
malignancies. It is a disease of the elderly and more commonly 
occurs in women, with a female to male ratio of 2:1.  
Fine needle aspiration biopsy is useful to establish the diagnosis.The 
cytological features are identical to squamous cells. Squamous cell 
carcinomas of the thyroid are strongly positive for CK19 but 
negative for CK1, CK4, CK10/13 and CK20(217). Occacional cases 
have been reported as positive for thyroglobulin, but these most 
likely represent non-specific absorption from adjacent cells; 
epithelial membrane antigen has also been reported to be positive  
and, only focally if at all positive for TTF-1.The tumours are graded 
as squamous carcinomas in other anatomic locations(26).  
1-2-5-7 Mucoepidermoid carcinoma (MEC) 
Defined as a malignant epithelial neoplasm showing  
a combination of epidermoid and mucinous components.  
 MEC comprises about 0.5% of all thyroid malignancies and shares 
most of the epidemiological features of papillary carcinoma. This 
tumour affects women more frequently than men (2:1). 
Macroscopically MEC shows considerable size variations and may 
measure up to 10 cm. The tumours are rubbery to firm and the cut 
surfaces show a tan-brown to yellowish-white, are well 
circumscribed but non-encapsulated masses. Cytologic smears show 
epidermoid cells and mucus-secreting cells with vacuolated 
cytoplasm often containing mucinous material, and/or signet-ring 
features.Tumour cells are positive for low and high molecular 
weight cytokeratins and usually for polyclonal CEA. Most MECs are 
focally positive for thyroglobulin and TTF-1 and negative for 
calcitonin. P-cadherin expression is found in most MEC. MEC is 
most likely derived from metaplastic follicular thyroid 
epithelium(27).  
1-2-5-8 Sclerosing  mucoepidermoid carcinoma with eosinophilia  
Is a rare malignant neoplasm showing epidermoid and glandiular 
differentiation, acompanied by prominent sclerosis  and by 
eosinophilic and lymphocytic infilteration.The tumor occurs in 
adults and affects women almost exclusively. Thyroiditis, in 
particular fibrosing Hashimoto,s thyroiditis has been reported in 
association with this tumour type. Most patient present with a slowly 
growing thyroid mass and rarely patients may present with 
symptoms resulting from extrathyroidal extension of the tumour. 
The tumor often shows ill-defined borders, although occasionally 
they may be well circumscribed.The cut surfaces are usually 
firm,white to yellow, and solid. The tumor is characterized by a 
sclerotic stroma richly infiltrated by eosinophils, lymphocytes and 
plasma cells. The tumour cells form anastomosing cords and nests. 
Interspersed with the epidermoid nests are mucous secreting cells 
and small pools of mucin. Rarely the tumour is associated with 
conventional papillary thyroid carcinoma.The background thyroid 
almost always shows Hashimoto,s thyroiditis or lymphocytic 
thyroiditis. The tumour is immunoreactive for cytokeratin, negative 
for calcitonin, and is usually negative for thyroglobulin. 
Approximately half of the cases are positive for TTF1. The tumour 
probably arises from follicuar epithelium-derived metaplastic 
squamous nests that occur in a setting of Hashimoto,s or 
lymphocytic thyroiditis. About half of the patients have been 
disease-free on follow-up of 3 months to 9 years, and about half 
have shown local-regional or distant spread. Predictive factors are 
notknown(28).  
 
1-2-5-9  Mucinous carcinoma: Is characterized by clusters of 
neoplastic cells surrounded by extensive extracellur mucin 
deposition. It is very rare with only a few cases reported and 
nothing is known about its epidemiology(29). 
 
 
 
 
 
 
1-2-5-10 Medullary thyroid carcinoma(MTC) (Solid 
carcinoma; solid carcinoma with amyloid stroma; C-cell carcinoma; 
compact cell carcinoma; neuroendocrine carcinoma of the thyroid).  
 
Defined as a malignant tumour of the thyroid gland showing C-cell 
differentiation.MTC comprises 5 to 10% of all thyroid malignancies.  
Two forms of medullary carcinoma exist: sporadic and familial. Up 
to 25% of these tumours are heritable. In sporadic cases, the mean 
age at presentation is 50 years with a slight female 
predominance.Tumours occurring in patients with MEN 2B present 
in infancy or early childhood while MEN 2A associated tumours 
occur in late adolescence or early adulthood. Sporadic forms of 
MTC occur with similar frequency in different parts of the 
world(30). 
Approximately 70-80% of medullary carcinoma are sporadic, and 
most such tumors are unilateral. In some centers, routine screening 
of calcitonin level in patients with nodular thyroid disease allow 
early diagnosis of unsuspected sporadic medullary thyroid 
carcinoma.In the series of Kaserer et al 63% of the patients 
undergoing thyroidectomy were found to have medullary 
carcinoma(with female predominance)(5)  
Fletcher(5) reported that medullary carcinoma comprises 5 to 10 % of all 
thyroid malignancies and the mean age at diagnosis for sporadic 
medullary thyroid carcinoma (MTC) is 44-50 years, and for familial 
MTC 41-43 years. The male to female ratio for sporadic MTC is 1:1.4 
and that for familial MTC 1:1.1(5). 
The etiology  of sporadic MTC is unknown. Rarely they may arise in 
the setting of Hashimoto,s disease, but this association is probably 
coincidental.Limited data suggest that chronic hypercalcemia may 
be associated with an increased incidence of these tumours.The 
incidence of MTC is not increased in patients with a history of 
irradiation to the head and neck; however, rats treated with low 
doses of 1311 have an increased incidence of these tumours. 
Medullary carcinoma typically is located in the middle third of the 
lobe, which corresponds to the area where C cells predominate 
normally. C-cell hyperplasia is the precursor of heritable medullary 
carcinoma but the role of C-cell hyperplasia in the development of 
sporadic medullary carcinoma remains unknown(30).The gene 
involved in the development of this tumor is RET, located on 
chromosome l0qll.2, which is affected in the form of various 
activating germline mutations.The development of medullary 
carcinoma is clearly age-related, a fact that guides the decision 
concerning the timing for the prophylactic thyroidectomy(30).About 
30% of tumours exhibit aneuploidy by flow or static cytometry. In 
some studies, aneuploidy and high growth fractions have been 
associated with worse prognosis. 
Little is known about the etiology of sporadic MTC. Somatic RET 
mutations, have been shown to occur in 20- 80% of sporadic MTC. 
Medullary carcinoma cells also express bcl-2 and c myc, but not Bax 
or p53. FMTC caused by gain of function germ-line mutations in the 
RET proto-oncogene with an autosomal dominant mode of 
inheritance. There is only a single differential diagnosis to consider 
for heritable forms of medullary thyroid carcinoma, multiple 
endocrine neoplasia type 2 (MEN2), which comprises MEN 2A, 
MEN 2B and familial medullary thyroid carcinoma(30,31). 
 Diagnosis   
Most patients with sporadic MTC present with a cold painless 
thyroid nodule. Up to 50% of patients may present with nodal 
metastases and up to 15% may have distant metastases.Virtually all 
MTCs produce calcitonin and serum levels of the hormone are 
typically increased. Since the tumour cells may produce a number of 
other peptide products and amines, paraneoplastic syndromes due to 
the release of these substances may occur(eg, Cushing syndrome). 
Macroscopically the tumours are firm, white-grey to tan in colour, 
gritty in consistency, and are circumscribed, but not encapsulated. 
Aspirates  are typically hypercellular with non-cohesive or loosely 
cohesive cells which  are variable in shape with polygonal, bipolar 
or spindle shapes. The nuclei are typically hyperchromatic with 
coarsely granular chromatin and moderate degrees of 
pleomorphism(30).  
The histopathologic appearance of MTC is quite variable. The 
characteristic features are sheets, nests or trabeculae of polygonal, 
round or spindle cells, separated by varying amounts of 
fibrovascular stroma, giving rise to a more or less lobular (organoid) 
or trabecular arrangement. Some tumours may have a histological 
pattern reminiscent of carcinoid. Nucleoli are usually not prominent 
(except in the oncocytic variant), and mitotic figures are usually 
scant. Mucin production has been described in a high proportion of 
cases, but it is usually present in limited amounts. Small 
psammomalike concretions may also be seen(30). 
Immunohistochemically, the tumor cells are reactive for epithelial 
markers such as keratin, general thyroid markers such as TT-F; pan-
endocrine markers such as NSE; chromogranin A,B and C; 
synaptophysin; opioid peptides(11).They are also consistently 
positive for CEA and generally negative for thyroglobulin.The 
tumour cells are immunoreactive for calcitonin in the vast majority 
of cases, with in-situ hybridization techniques revealing calcitonin 
mRNA in the remaining cases(32). 
MTC tends to metastasize early, particularly to cervical lymph 
nodes. Distant metastases are found at operation in approximately 
20% patients who present with palpable MTC. Hematogenous 
metastasis often occur in the liver, lungs, and bone. 
Microcarcinomas may also be associated with metastases(30). 
Ultrastructurally, the tumour cells contain two main types of 
secretory granules: type I granule, and type II granules(11).  
Treatment  
The primary treatment is total thyroidectomy (particularly important 
for the familial form because of the multicentricity and C-cell 
hyperplasia) and cervical lymphadenectomy(34).  
Prognosis and predictive factors  
United States SEER data of 499 cases of medullary carcinoma 
showed 5 and 10- year survivals of 83.2% and 73.7%, respectively . 
Older age, male gender and extent of local tumour invasion were 
associated with substantially reduced survival. In the series reported 
by Kebebew et aI(33), overall cause specific mortality in familial 
cases at 5 and 10 years was 10.7% and 13.5%, respectively. In 
univariate analyses, age, gender,TNM stage, sporadic vs hereditary 
status, distant metastases and extent of thyroidectomy were 
significant prognostic factors. However, only age and stage were 
significant variables in multivariate analyses.These observations 
underscore the fact that screening and early treatment by 
thyroidectomy, with central lymph node dissection, are associated 
with a rate of cure approaching 100%(33).  
 1-2-5-11 Mixed medullary and follicular cell 
carcinoma (MMFCC) 
MMFCC are tumours showing the morphological features of both, 
medullary carcinoma with immunoreactive calcitonin and 
follicular(or papillary) carcinomas with immunoreactive 
thyroglobulin. They are very rare tumours and most have been 
described in single case reports(35).  
 
1-2-5-12 Spindle cell tumour with thymus-like 
differentiation (SETTLE) 
SETTLE is a rare, malignant tumour of the thyroid characterized by 
a lobulated architecture and biphasic cellular composition featuring 
spindle shaped epithelial cells that merge into glandular structures. 
They usually affects children, adolescents and young adults, with a 
mean age of 19 years (range 4-59), and a male 
predominance(M:F=1.5:1).Most cases are biphasic, but occasional 
cases may be composed exclusively of spindle cells or glandular 
structures, the so-called monophasic variant. Both the spindle and 
glandular cells express cytokeratins. Rarely, the spindle cells may 
demonstrate myoepithelial differentiation. The tumour cells are 
negative for thyroglobulin, calcitonin, CEA, S-100 protein and CD5 
Ultrastructurally, the epithelial nature of the spindle cells is 
evidenced by presence of tonofilaments, desmosomes and basal
 lamina(36).  
  
1-2-5-13  Carcinoma showing thymus-like 
differentiation (CASTLE) 
CASTLE is a carcinoma of the thyroid gland with architectural 
resemblance to thymic epithelial tumours.The great majority of 
cases occur in the thyroid gland, most commonly the lower poles, 
but rare cases may arise in the perithyroid soft tissues of the neck.  
 CASTLE is a very rare tumour that affects middle-aged adults with 
a slight female predominance (M:F=1:1.3). Grossly, the tumour 
is fleshy and grey-tan. It grows in the form of variably sized 
smooth-contoured islands and cords, and occasionally jagged 
islands, accompanied by a moderately cellular desmoplastic 
stroma.The architecture thus shows a superficial resemblance to the 
lobulation seen in thymomas and thymic carcinomas.The 
immunophenotype of CASTLE is identical to that of thymic 
carcinoma(37).  
 
1-2-5-14 primary lymphoma and plasmacytoma  
Defined as primary lymphoma arising within the thyroid. Primary 
thyroid gland lymphomas are uncommon and have been estimated to 
represent approximately 5% of all thyroid tumours, and 2.5-7% of 
all extra-nodal lymphomas.They occur predominantly in older 
individuals (mean age, 65 years) with a female to male ratio of
 3-7:1. Most cases are seen in adult or elderly females. 
Most cases of extranodal marginal zone B cell lymphoma of the 
thyroid gland are associated with chronic lymphocytic thyroiditis. It 
has been postulated that lymphomas arise in the setting of acquired 
mucosa-associated lymphoid tissue (MALT) as a result of an 
autoimmune or inflammatory process. Patients with Hashimoto,s 
thyroiditis have a strikingly higher incidence of thyroid lymphoma 
when compared to sex and age- matched healthy individuals. 
Primary thyroid lymphomas should be distinguished from 
lymphomas which arise elsewhere in the neck or mediastinum with 
secondary involvement of the thyroid gland(38).  
The tumor presents as one or more cold nodules on thyroid scan. 
Macroscopically there is a wide variation in tumour size, ranging up 
to 20 cm in maximum dimension.The cut surfaces are smooth or 
slightly bulging, pale tan, white-grey or red with a “fish-flesh” 
appearance. Aspirates from large cell lymphomas are typically 
hypercellular with non-cohesive cells showing cytological features 
similar to those of large cell lymphomas in other sites.The 
lymphomas of the thyroid include extranodal marginal zone B-cell 
lymphoma (EMZBCL), and diffuse large B- cell lymphoma 
(DLBCL) with areas of transition between the two types. Other 
types of lymphoma, specifically follicular lymphoma, have been 
described, but are rare. Immunohistochemically, all types of thyroid 
lymphomas exhibit consistent positivity for CD45, and nearly all of 
them show markers indicative of B-cell derivation(39). An important 
diagnostic finding is the packing of follicular lumina by lymphoid 
cells (“lymphoepithelial lesions”), a feature usually not present in 
thyroiditis. Clonal rearrangement of the heavy chain variable region, 
and Fas gene mutations have been reported in thyroid lymphomas, 
as well as monoclonal rearrangements of the immunoglobulin
 heavy chain gene. The prognosis of thyroid MALT type 
lymphomas is very favorable in general, although it is dependent on 
clinical stage and histology. Patients whose tumours have either a 
large cell component or are composed of large B- cells, have a 
significantly poorer prognosis(38). 
Plasmacytoma  
Plasmacytomas are rare in the thyroid, and it has been suggested that 
these lesions may represent a MALT type lymphoma with prominent 
plasma cell differentiation(38).. 
 
1-2-5-15  Secondary tumours of the thyroid  
Metastases to the thyroid gland are found at autopsy in up to 25% of 
patients  with dissiminated malignancies. In clinical series, the 
frequency of secondary involvement of thyroid is considerably 
lower. In the series of cases reported by Heffes et al(40) 42% of the 
glands with metastases showed other abnormalities. Metastases 
involving preexisting thyroid carcinomas have also been 
documented. In one series of renal cells carcinomas metastatic to the 
thyroid, 80% of the cases involved a single lobe and presented as a 
solitary mass. Fine needle aspiration biopsy is a useful approach for 
the diagnosis of secondary tumours of the thyroid. A source of 
difficulty is the distinction of metastatic disease from poorly 
differentiated or undifferentiated thyroid carcinomas. Most tumours 
involving the thyroid by direct extension are squamous cell 
carcinomas or malignant lymphomas. Metastatic tumours generally 
retain the histologic features of the primary tumours but are 
frequently less differentiated.The distinction of metastatic renal cell 
carcinoma from follicular tumours showing clear cell change may be 
particularly difficult. Features favoring a diagnosis of metastatic 
renal cell carcinoma include prominent vascularity, glandular lumina 
filled with red blood cells and clear cytoplasm, aided by the absence 
of thyroglobulin in the neoplastic cells and the presence of 
CD10(40). 
It should be noted, however, that interstitial deposits of 
thyroglobulin may be present in metastases involving the thyroid 
gland and in some instances, thyroglobulin may diffuse into the 
tumour cell cytoplasm. Stains for TTF-1 are more reliable in this 
situation since a positive reaction is manifested by nuclear rather 
than cytoplasmic staining. A subset of secondary tumours from the 
lung would also be TTF-1 positive. Metastatic neuroendocrine and 
carcinoid tumours may be particularly difficult to distinguish from 
medullary thyroid carcinomas. The diagnosis of metastatic 
neuroendocrine tumours should be suspected in the presence of a 
predominantly interstitial pattern of spread, the occurrence of 
multiple tumour foci, folliculotropism, rosette formations with 
lumens and lack of immunoreactivity for calcitonin and CEA. 
Although solitary thyroid prognosis of patients with metastases to 
the thyroid gland is generally poor, surgical resection of solitary 
thyroid metastatic disease is recommended. This approach may lead 
to prolonged survival, particularly in patients with renal cell 
carcinoma(40). 
Origin of metastases  
In the clinical series reported by Nakhjavani et al(41), the most 
common primary sites were kidney (33%), lung (16%), uterus (7%), 
and melanoma (5%). Breast, lung and skin (melanoma) have been 
the most common sites of origin of metastases in autopsy series. In 
one study from Hong Kong(41), the majority of the tumours 
secondarily involving the thyroid gland were carcinomas, and of 
these cases, lung was the most common (43%), followed by breast 
(8.8%) and stomach (7.7%). Lymphomas and leukemias accounted 
for 15% of cases. Rare sources of primary tumours included 
nasopharyngeal carcinoma, choriocarcinoma, malignant
 phylloides tumour and osteosarcoma(41). 
 
 
 
 
 
 
1-3 OBJECTIVES 
 
 
1-2-1 General objective: 
To study the pattern of thyroid tumors among Sudanese 
patients diagnosed at National Health Laboratory (NHL), 
Radiation and Isotope Center-Khartoum (RICK) and Soba 
University  Hospital (SOH) from January 2007 through to 
December 2009 to determine the histopathological and 
epidemiological features of these tumors so as to improve 
the outcome and  quality of thyroid tumor care.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1-3-2 Specific objectives: 
1- To determine the prevalence of thyroid tumors 
among Sudanese patients diagnosed at NHL,RICK 
and SOH.   
2- To determine the histopathological pattern of thyroid 
tumors among the studied group. 
3- To determine the age, sex , residency distribution 
,risk factors  and clinical presentation of thyroid 
tumors in the mentioned group. 
4- To determine the common diagnostic procedures 
used for the diagnosis of thyroid tumors among 
Sudanese patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTE TWO  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2- METHODOLOGY 
 
2-1- Study design:  
This is a descriptive retrospective study.   
 
2-2- Study field:  
The study was carried out at the National Health 
Laboratory (NHL), Radiation and Isotope Center-Khartoum 
(RICK) and Soba University Hospital (SOH).  
 
The National Health Laboratory is a National reference 
laboratory located in the center of Khartoum. It has 
several pathologic departments including a histopathology 
department and Cancer Research Center of Sudan. NHL is 
guided by a professional cadre and receives samples from 
different parts of Sudan.  
 
Radiation and Isotope Center-Khartoum is a specialized 
referral hospital for diagnosis and management of 
malignancy. It receives patients from different parts of 
Sudan. 
 
Soba University Hospital (SOH) is a teaching hospital that 
belongs to University of Khartoum- School of Medicine. It 
comprises various medical departments, as well as a 
laboratory made up of different departments including a 
histopathology service. 
 
2-3- Study population and duration:  
All cases of thyroid tumors that presented to NHL, RICK 
and SOH from January 2006 through to December 2008. 
 
 
2-4- Inclusion criteria: 
Cases of thyroid tumors that were diagnosed 
histopathologically at the three mentioned centers with or 
without fine needle aspiration cytology or radiological 
investigations were included in the study. 
 
2-5- Exclusion criteria: 
1- Thyroid tumor cases that had no histopathology 
slides in the histopathology laboratories of the three 
mentioned centers were excluded from the study.  
According to this criterion ten cases were excluded, 8 
in NHL, 1 in RICK and 1 in SOH. 
2- Any case with inadequate information was excluded 
from the study. Accordingly, nine cases were 
excluded, 2 cases were in NHL, 5 in RICK and 2 in 
SOH. 
 
3- Poorly stained slides. No slide had to be excluded 
according to this criterion. 
 
2-6- Materials and methods: 
Data were collected from patient's request forms in a pre-
designed questionnaire (appendix). All the histopathological 
slides of the study were retrieved and reviewed with the 
help and supervision of experienced histopathologists to 
revise the histopathological type of the tumors. 
 
The microscopic pictures were obtained using Olympus BX 
51 and DP 70 video-microscopy system at NHL.    
 
2-7- Data processing and statistical analysis:  
The data were electronically processed and analyzed using 
computer S.P.S.S program, version 11.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER THREE 
 3-RESULTS 
There were 937 thyroid samples received at National Health 
Laboratory (NHL), Radiation and Isotope Center-Khartoum 
(RICK) and Soba University Hospital (SOH) during the three 
years of the study. One hundred and sixteen cases (116), were 
diagnosed in these three centers histopathologically as thyroid 
tumors. Review of   patient sheets and slides excluded 19 cases 
according to the exclusion criteria of the study (see the exclusion 
criteria). The remaining 97 cases were analyzed. 
The results of the study are shown in the following tables: 
 
Table 1 Total numbers of histopathology samples, thyroid samples, the 
numbers and percentage of thyroid tumors.*  
 
Center Total histopathologysamples 
Thyroid 
samples 
No of included 
thyroid tumors
% of thyroid  
tumors * 
SOB 5078 89 (9.5%) 14 0.3 
RICK 3367 142 (15.2%) 15 0.4 
NHL 14789 706  (75.3%) 68 0.5 
Total 23234 937 (100%) 97 0.4 
* Expressed as the proportion of total histopathologic samples in each center 
 
 
 
 
  
 
 
Table 2 Classification of the total thyroid samples and the prevalence 
of thyroid tumors 
Tumor Number Prevalence* 
Follicular adenoma 70 7.5% 
        Malignant tumor 27 2.9% 
      Non-neoplastic swelling 840 - 
Total 937 - 
*Expressed as the proportion of goitrous samples 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 3 the minimum, maximum, mean, range, and standard deviation 
of  the  ages  of  the  97  patients  with  thyroid  tumors  included  in  the 
study. 
 
 
Range Minimum Maximum Mean Standard deviation 
Age (in 
years) 68 12 80 37.54 14.722 
 
Table 4 Age distribution of the 97 patients with thyroid tumors  in the 
study. 
Age group Frequency Percent% 
From 0  to  <10 years 0 0 
From10 to <20 years 7 7.2 
From 20 to <30 years 24 24.7 
From 30 to <40 years 27 27.8 
  Fom40 to <50 years 19 19.6 
From 50 to <60 years 9 9.3 
From 60 to <70 years 7 7.2 
From 70 to <80 years 2 2.1 
From 80 to <90 years 2 2.1 
  From 90 and more 0 0 
Total 97 100.0 
 
 
Table 5 Distribution of thyroid tumors according to age groups* 
Diagnosis  
Age group 
 Follicular 
adenoma 
Follicular 
carcinoma
Papillary 
carcinoma
Medullary 
carcinoma
Anaplastic 
carcinoma 
 
Total 
Count 7 0 0 0 0 7 From 10 
to to < 
20years 
% of 
Total 7.2% 
 
0 
 
0 
 
0 
 
0 7.2% 
Count 18 1 4 1 0 24 
From 20 
to < 30 
years 
% of 
Total 18.6% 1.0% 4.1% 1.0% 
 
0 
 
24.7% 
Count 21 2 3 1 0 27 From 30 
to < 40  
years 
% of 
Total 21.6% 2.1% 3.1% 1.0% 
 
0 27.8% 
Count 16 0 2 0 1 19 From 40 
< 50  
years 
% of 
Total 16.5% 
 
0 2.1% 
 
0 1.0% 19.6% 
Count 4 2 1 1 1 9 From 50 
to < 60 
years 
% of 
Total 4.1% 2.1% 1.0% 1.0% 1.0% 9.3% 
Count 2 3 2 0 0 7 From 60 
to < 70 
years 
% of 
Total 2.1% 3.1% 2.1% 
 
0 
 
0 7.2% 
Count 1 1 0 0 0 2 From 70 
to < 80 
years 
% of 
Total 1.0% 1.0% 
 
0 
 
0 
 
0 2.1% 
Count 1 0 0 0 1 2 From 80 
to < 90 
years 
% of 
Total 1.0% 
 
0 
 
0 
 
0 1.0% 2.1% 
Count 70 9 12 3 3 97 
Total % of 
Total 72.2% 9.3% 12.4% 3.1% 3.1% 100.0%
• Expressed as the proportion of all thyroid tumors. 
 
 
 
  
 
Fig.1 Age distribution of the 97 patients of thyroid tumors. 
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Table 6 Sex distribution of the 97 patients with thyroid tumors  in the 
study.  
Sex Frequency Percent% 
Male 13 13.4% 
   Female 84 86.6% 
Total 97 100.0% 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 7 Distribution of thyroid tumors in males* 
Diagnosis  
Count / 
percentage Follicular 
adenoma 
Papillary 
carcinoma
Follicular 
carcinoma
Medullary 
carcinoma
Anaplastic 
carcinoma 
Total
Count 8 3 1 1 0 13 
% of Total 61.5% 23.1% 7.7% 7.7% 0 100%
* Expressed as the proportion of thyroid tumors in males. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 8 Distribution of thyroid tumors in females* 
Diagnosis       Total Count 
/% Follicular 
adenoma 
Papillary 
carcinoma
Follicular 
carcinoma
Anaplastic 
carcinoma
Medullary 
carcinoma  
Count 62 9 8 3 2 84 
% of 
Total 73.8% 10.7% 9.5% 3.6% 2.4% 100%
* Expressed as the proportion of thyroid tumors in females. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 9 Distribution of each thyroid  tumor diagnosed in the study 
according to sex*  
Sex/count Follicular adenoma 
Follicular 
carcinoma
Papillary 
carcinoma
Medullary 
carcinoma 
Anaplastic 
carcinoma Total 
Count 8 1 3 1 0 13 
Male % of 
Total 11.4% 11.1% 25% 33.3% 0 13.4% 
Count 62 8 9 2 3 84 
 Female % of 
Total 88.6% 88.9% 75% 66.7% 100% 86.6% 
Count 70 9 12 3 3 97 
Total % of 
Total 100% 100% 100% 100% 100% 100.0%
*Expressed as the proportion of each thyroid tumors 
 
 
 
 
 
 
 
 
  
 
 
 
Table 10 Distribution of the 70 cases of follicular adenoma diagnosed 
in the study according to age group. 
Age group Frequency Percent% 
From 0 to < 10 years 0 0 
From 10 to <20 years 7 10.0 
From 20 to <30 years 18 25.7 
From 30 to <40 years 21 30.0 
From 40 to <50 years 16 22.9 
From 50 to <60 years 4 5.7 
From 60 to <70 years 2 2.9 
From 70 to <80 years 1 1.4 
From 80 to <90 years 1 1.4 
Total 70 100.0 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
Fig.2 Distribution of   the 70 cases of follicular adenoma diagnosed in 
the study according to age group. 
 
 
 
 
 
 
 
0%
10%
25.70%
22.90%
5.70%
2.90%
1.40%1.40%0%
30.00%
0%
5%
10%
15%
20%
25%
30%
35%
    From 0
  to < 10
years
 From10
to <20
years
From
20 to
<30
years
  From
30 to
<40
years
From40
to <50
years
From
50 to
<60
years
From
60 to
<70
years
From
70 to
<80
years
From
80 to
<90
years
> 90
  
 
 
 
 
Table 11 Distribution of the 70 cases of follicular adenoma diagnosed in 
the study according to sex.  
Sex Frequency Percent% 
                   Male 8 11.4 
Female 62 88.6 
Total 70 100.0 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table  12  The  types  of  thyroid  cancers  of  the  27  cases  of  malignant 
thyroid tumors in the study*.    
Type Frequency Percent%
Papillary carcinoma 12 44.5 
Follicular carcinoma 9 33.3 
Medullary carcinoma 3 11.1 
Anaplastic carcinoma 3 11.1 
Total 27 100.0 
*Expressed as the proportion of malignant thyroid tumors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table  13  Distribution  of  the  27  cases  of    malignant  thyroid  tumors 
diagnosed in the study according to age group *. 
Age group / 
count 
Follicular 
carcinoma
Papillary 
carcinoma
Medullary 
carcinoma
Anaplastic 
carcinoma Total 
Count 1 4 1 0 6 
From 20 to 
<30 years % of 
Total 3.7% 14.8% 3.7% 
0 22.2%
Count 2 3 1 0 6 From 30 to 
<40 years % of 
Total 7.4% 11.1% 3.7% 
0 22.2%
Count 0 2 0 1 3 From 40 
to<50years % of 
Total 
0 7.4% 0 3.7% 11.1%
Count 2 1 1 1 5 
From 50 to 
59 years % of 
Total 7.4% 3.7% 3.7% 3.7% 18.5%
Count 3 2 0 0 5 
From 60 to 
<60 years % of 
Total 11.1% 7.4% 
0 0 18.5%
Count 1 0 0 0 1 From 70 to 
<80 years % of 
Total 3.7% 
0 0 0 3.7% 
Count 0 0 0 1 1 
From 80 to 
<90 years % of 
Total 
0 0 0 3.7% 3.7% 
Count 9 12 3 3 27 
Total % of 
Total 33.3% 44.4% 11.1% 11.1% 100.0%
*Expressed as the proportion of malignant  thyroid tumors 
 
  
 
 
 
 
Table  14  Distribution  of  the  27  cases  of    malignant  thyroid  tumors 
diagnosed in the study according to sex*. 
Sex / count  Follicular carcinoma 
Papillary 
carcinoma
Medullary 
carcinoma
Anaplastic 
carcinoma Total 
Count 1 3 1 0 5 
 Male 
% of Total 3.7% 11.1% 3.7% 0 18.5%
Count 8 9 2 3 22 
 Female 
% of Total 29.6% 33.3% 7.4% 11.1% 81.5%
Count 9 12 3 3 27 
Total % of 
Total 33.3% 44.4% 11.1% 11.1% 
100.0
% 
*Expressed as the proportion of malignant  thyroid tumors 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 15 The mean, standard deviation, minimum and maximum age of 
each thyroid tumors.  
Age in year Follicular 
adenoma 
Papillary 
carcinoma
Follicular 
carcinoma
Medullary 
carcinoma
Anaplastic 
carcinoma 
   Mean 34.8 37.67 51.22 39.67 58.33 
   Standard 
deviation 
13 14.386 16.323 13.614 20.207 
Minimum 12 20 27 29 40 
Maximum 12 20 70 55 80 
 
 
 
 
 
 
 
 
 
 
 
 
Table 16  Age distribution of the twelve cases of  papillary carcinoma   
Age group Frequency Percent% 
             From 20 to <30  years 4 33.3 
             From 30 to <40 years 3 25.0 
             From 40 to <50 years 2 16.7 
            From 50 <60 years 1 8.3 
            From 60 < 70 years 2 16.7 
Total 12 100.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3  Distribution  of  age  group  of  the  twelve  cases  of  papillary 
carcinoma.   
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 Table 17 Age distribution of the nine cases of  follicular carcinoma  
Age group Frequency Percent% 
From 20 to < 30 years 1 11.1 
From 30 to < 40 years 2 22.2 
From 50 to < 60 years 2 22.2 
From 60 to < 70 years 3 33.3 
From 70 to < 80 years 1 11.1 
Total 9 100.0 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4 Distribution of age group for the nine cases of  follicular 
carcinoma. 
 
0%
11.10%
22.20%
0%
22.20%
33.30%
11.10%
0%
5%
10%
15%
20%
25%
30%
35%
< 20 yearsFrom 20 
to < 
30 years
From 30 
to <
40 years
From 40 
to < 
50 years
From 
50 to <
60 years
From 
60 to <
70 years
From 70 
to  < 
80 years
  
Table 18 Age distribution of the three cases of  medullary carcinoma  
Age group Frequency Percent% 
From 20 to < 30 years 1 33.3 
From 30 to < 40 years 1 33.3 
From 50 to < 60 years 1 33.3 
Total 3 100.0 
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Fig.5    Distribution  of  age  group  for  the    three  cases  of    medullary 
carcinoma. 
 
 
 
Table 19 Age distribution of the three cases of anaplastic carcinoma     
Age Frequency Percent% 
From 40 to < 50years 1 33.3 
From 50 to < 60 years 1 33.3 
        From 80 to < 90years 1 33.3 
Total 3 100.0 
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Fig.6    Distribution  of  age  group  for  the  three  cases  of  anaplastic 
carcinoma.     
 
 
 
 
 
 
 
Table  20  Grouping  of  the  27  cases  of  malignant  thyroid  tumors  
according to behavior(Fletcher (5)). 
Tumor behavior group Types No of 
cases 
Papillary carcinoma 12  
Low- grade malignant Follicular carcinoma 
minimally invasive 
2 
Follicular carcinoma 
widely invasive 
7  Intermediate–grade malignant 
Medullary carcinoma 3 
 High-grade malignant Anaplastic carcinoma 3 
total  27 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Table 21 Distribution of clinical presentation of thyroid tumors(N=97). 
Symptoms Yes Unspecified Valid percent% 
Anterior neck swelling 60 37 61.9 
   Hoarsness 1 96 1 
   Dyspnea 1 96 1 
   Dysphagia 1 96 1 
   Cough 0 97 0 
   Hemoptysis 0 97 0 
 
 
 
 
 
  
 
 
Table  22  Distribution  of  diagnostic  procedures  used  for    thyroid 
tumors in the study(N=97).  
Diagnostic procedure Done Unspecified Valid percent%
  Surgical resection biopsy 97 0 100 
  FNAB 14 83 14.4 
  CT scan 0 97 0 
  Ultrasound 0 97 0 
 Radionuclide iodine scan 0 97 0 
  MRI 0 97 0 
  Thyroid function test  1 96 1 
  Amyloid stain 1 96 1 
  Immunohistochemistry 0 97 0 
  Serum calcitonin  0 97 0 
 
 
 
 
 
 
 
 
  
 
 
 
Table 23 Results of  the 14 cases of FNABs.  
Result Frequency Percent% 
        Colloid nodule 3 21.4 
Anaplastic carcinoma 2 14.3 
        Suscpicous tumor 2 14.3 
        Malignant tumor 3 21.4 
        Benign tumor 4 28.6 
Total 14 100.0 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 24 Types of specimens for the 97 cases of thyroid tumors in the 
study. 
Type of specimen Frequency Percent% 
        Excisional biopsy 7 7.2 
        Lobectomy 22 22.7 
Subtotal thyroidectomy 11 11.3 
       Total thyroidectomy 2 2.1 
      Unspecified thyroidectomy 42 43.3 
       Unmentioned operation 13 13.4 
Total 97 100.0 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.7  Follicular adenoma of thyroid gland showing part of the 
surrounding  capsule(H&E  X10). 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8  Psammoma bodies in papillary carcinoma of thyroid gland 
(H&E  X40). 
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Fig.9 Nuclear pseudoinclusion (arrow)in papillary carcinoma of 
thyroid gland (H&E  X40). 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10 Follicular carcinoma of thyroid gland, widely invasive type 
(H&E  X10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11 Medullary carcinoma of thyroid gland (H&E  X10). 
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Fig. 12  Anaplastic carcinoma of thyroid gland showing numerous 
mitotic figures(arrow) (H&E  X40). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER    FOUR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4-1- DISCUSSION 
 
Thyroid cancer is fairly common; the annual incidence rate ranges 
from 0.5 to 10 cases per 100 000 population(5).They represent the 
most common malignancies of the endocrine system and occur 
primarily in young and middle aged adults and are rare in 
children(2). Numerous studies have demonstrated that thyroid cancer 
is two to four times more frequent in females than in males, but this 
sex difference is far less pronounced in children and older adults(2). 
Literature reviewing showed no previous histopathological studies 
concerning thyroid tumors were carried out in Sudan. So this is the 
first histopathological study of thyroid tumors in Sudan. 
Referring to Table 1, the total number of thyroid samples 
represented 4% (937 samples)of the total histopathological samples 
(23234 samples) received at National Health Laboratory (NHL), 
Radiation and Isotope Center –Khartoum (RICK) and Soba 
University Hospital (SOH). At NHL thyroid samples represented  
3% of the total histopathological samples received at it, 0.6% at 
RICK and 0.4 at SOH, of the total histopathological samples 
received at each.  
The 937 thyroid samples were distributed as follow:  
At the NHL 708 (75.3%) of thyroid samples were received. Seventy 
nine(79) of them  were diagnosed as thyroid tumors and 68 were 
included in this study. Thyroid tumors represented 0.5% of the total 
histopathology samples received at NHL. 
At RICK 142(15.2%) were thyroid samples, 22 of them were 
diagnosed as thyroid tumors and 15 were included in this study. 
Thyroid tumors represented 0.4% of the total histopathology 
samples received at RICK. 
At SOH 89 (9.5%) were thyroid samples. Seventeen were diagnosed 
as thyroid tumors and 14 were included in the study. Thyroid 
samples represented 0.3% of the total histopathology samples 
received at SOH. 
The study concluded that the prevalence of thyroid tumors among 
histopathology samples was 0.4%.  
The study showed that the prevalence of follicular adenoma among 
goitrous patients was 7.5% and that of malignant tumor was 2.9 % 
(Table 2). It may not be the exact incidence because many  cases are 
diagnosed in private laboratories and other hospital laboratories that 
were not included in this study. The actual number of thyroid 
cancers is most probably higher, but since the three selected 
institutions are the main histopathology centers in Sudan, we can 
considered these results are acceptable. In Sudan as in most 
developing countries, there is at present no reliable statistical 
information on absolute cancer rates. 
Table 3, showed that the minimum age affected by thyroid tumors 
was 12 years and the maximum was 80 years with a mean of 37 
years, a range of 68 years and a standard deviation of 14.722. 
Examination of Table 4 and Figure 1 show that the commonest age 
group affected by thyroid tumors in the study was 30 to < 40 years, 
showing the highest percentage of thyroid tumors 27 cases (27.8%), 
followed by the age group 20 to < 30  24 cases (24.7%), then the age 
group 40 to < 50 years with 19 cases (19.6%). No thyroid tumor 
occurred in <10 years or > 90 years old in the study.  72.1% of 
thyroid tumors were diagnosed in the ages from 20 to <50 years. 
Based on these findings we can conclude that young and middle 
aged adults were the most commonly affected by thyroid tumors. 
Children were rarely affected.  
Table 5 showed that the most common thyroid tumor was follicular 
adenoma constituting 72.2%(70 cases) followed by papillary 
carcinoma 12.4%(12 cases), and follicular carcinoma 9.3% (9 
cases), medullary carcinoma 3.1% (3 cases) and anaplastic 
carcinoma 3.1%( 3 cases)of all thyroid tumors. 
Table 6 showed that male patients constituted 13.4%(13 cases), 
compared to 86.6% female patients  (84 cases), with a male to 
female ratio of  1:6.5. As a conclusion females are more commonly 
affected by thyroid tumors than males.  
In males the most common thyroid tumors in the study was 
follicular adenoma constituting 61.5%(8 cases) of all thyroid tumors 
in males, followed by papillary carcinoma 23.1%(3 cases) and then 
by follicular carcinoma 7.7%(1 case) and medullary carcinoma 
7.7%( 1 case). No anaplastic carcinoma was diagnosed in males in 
the study (Table 7). 
In females the most common thyroid tumors was follicular adenoma 
73.8%(62 cases) of all thyroid tumors in females, followed by 
papillary carcinoma 10.7%(9 cases), and then follicular carcinoma 
9.5%(8 cases) and anaplastic carcinoma 3.6%(3 cases) and finally 
medullary carcinoma 2.4%(2 cases) of all thyroid tumors in females 
(Table 8). 
Referring to Tables 9 and 10 and Figure 2, the study showed that 
follicular adenoma (Fig. 7) was diagnosed in 70 cases (62 females 
and 8 males). It is the most common thyroid tumors constituting 
(72.2%) of all thyroid tumors. This finding is consistent with that 
reported by Ackerman (11), who stated that follicular adenoma is the 
most common thyroid neoplasm. 
The study showed that the peak age of incidence of follicular 
adenoma was 30 to <40 years (30%) followed by 20 to <30 years 
(25.7%) and then the 40 to < 50 years (22.9%). Follicular adenoma 
occurred in 78.6% in the age 20 to <50 years, 11.4% in >50 years of 
age and in 10%  occurred in age <20 years. The mean age of 
occurrence was 34.8 and the age range between 12-40 years. It 
occurred most commonly in adults aged 20 to <50 years (78.6%). 
This result is similar to that reported by Fletcher (5). The male to 
female ratio was 1: 7.75 (Table 11), but this result is somewhat 
different from that reported by  Fletcher(5) who stated that the male 
to female ratio is 1:6. Since two male cases of follicular adenoma 
were omitted from the study because their age was not mentioned. 
This could explain the high female ratio in this study. 
Table 12 and 13 showed that malignant thyroid tumors were 
diagnosed in 27 cases out of 97 cases of thyroid tumors in the study 
(22 females, 5 males). Malignant thyroid tumors represent 27.8% of 
total thyroid tumors. Papillary carcinoma was the most common 
constituting 44.5%(12 cases), followed by follicular carcinoma 
which constituted 33.3% (9 cases). Anaplastic and medullary 
carcinoma each constituted 11.1% ( 3 cases each). This finding is in 
concordance with that reported by Fletcher(5) who stated that the 
most common primary malignant thyroid tumors is papillary 
carcinoma, followed by follicular carcinoma, then medullary 
carcinoma and anaplastic carcinoma. No other types of thyroid 
malignancies were diagnosed in the study and also no metastatic 
case was diagnosed. This finding may be attributed to the size of the 
sample which was 97 cases of thyroid tumors.   
 
The highest percentage of thyroid cancers occurred in the age group 
> 20 to < 50 years (55.5%).  22.2% of cases occurred  in the age 
group 20 to < 30 and also the same percentage occurred in the age 
group 30 to < 40 years. The age group 40 to < 50 constituted 11.1%, 
and the age group >70 constituted 7.4%. No malignant thyroid 
tumors were diagnosed in the ages < 20 and  > 80 years. Delellis RA 
et al (2) stated that thyroid cancers occurs primarily in young and 
middle aged adults and is rare in children. The study revealed that 
thyroid cancers was rare in children, and occurred  primarily in 
young and middle aged adults a result that is in concordance with 
that reported by Delellis RA et al (2). Other series(4) have shown 
that thyroid cancer, is on average, diagnosed at a younger age in 
Middle East compared with the average of 45 years in the United 
States. This study revealed that thyroid cancers occurred in a 
comparable ages to  those in Middle East countries(4). Ronckers C 
et al (4) reported that in the Middle East countries as well as United 
States, patients aged 30- 49 years at diagnosis contributed a 
substantial proportion of thyroid cancers, ranging from more than 
30% to nearly 50% of all cases. In this study the age group 30 to < 
50 years contributed 33.3%, which fell within the Middle East 
countries range.       
The study showed that thyroid cancers were  more common in 
females (22 cases) compared to males (5 cases), with a male to 
female ratio of 1:4.4 (Table 14). This finding is consistent to that 
reported by Delellis RA et al (2) who stated that numerous studies 
have demonstrated that thyroid cancer is two to four times more 
frequent in females than in males. 
Robbins(1) reported that benign neoplasms outnumber thyroid 
carcinomas by a ratio of nearly 10:1. In this study the ratio of benign 
thyroid tumors to that of thyroid carcinomas was 3:1. This ratio may 
point to that there were small numbers of follicular adenomas 
diagnosed relative to thyroid carcinomas. This difference may be  
explained by the small number of thyroid tumors analyzed since not 
all thyroid samples are sent to histopathological examination. 
Another probable  reason may be that there is more tendency to 
diagnose hyperplasic nodule rather than follicular adenoma. Also 
there may be cases of follicular adenoma missed within multinodular 
goiter cases.  This issue needs further evaluation.   
Referring to Table 12 and Figure 3, papillary carcinoma (Fig. 8 and 
9) is the most prevalent thyroid malignancy in the study constituting 
44.5% of thyroid malignancies (12 cases). The peak age of incidence 
was 20 to < 30 (33.3%), followed by 30 to <40 age group (25%), 
and then 40 to < 50 (16.7%). Twenty five percent(25%)occurred in 
the age <50 years. The 3rd and 5th decades together constituted 
41.7% of papillary carcinomas. Seventy five (75%) percent of 
papillary carcinomas occurred in the ages 20 to <50.  No case was 
diagnosed in patients below 20 years of age. The study concludes 
that most papillary carcinomas were diagnosed in the second to fifth 
decades. Sternburg(17) stated that most papillary tumors are 
diagnosed in the 3rd and 5th decade. This difference may be due to 
the fact that the female patients - who made up the vast majority of 
the study cases – tend to give a lesser age than their actual age. 
Another probable reason is that the age structure of the population in 
Sudan may be much younger than that in developed countries. 
The study showed that the papillary carcinoma was the most 
common histological type among thyroid cancers 44.5%( 12 cases). 
This figure is lower than that reported by Fletcher(5) who reported 
that papillary carcinoma is the commonest histological type 
constituting 70-80% of thyroid cancer. However papillary carcinoma 
was the commonest thyroid  malignancy among the cases of the 
study. This lower prevalence of papillary carcinoma may be due to 
less exposure of Sudanese patients to risk factors such as radiation. 
This aspect awaits further study. 
Table 15 showed that the mean age of papillary carcinoma in the 
study was 37.8 years. The minimum age was 20 years and the 
maximum was 60 years with an age range of 40 years. Nine females 
and three males were diagnosed with a male to female ratio of 1:3 
(Table 14)). Fletcher (5) reported that the mean age was 43 years and 
the male to female ratio 1:2.5. The mean age in the study was a little 
bit less but the male to female ratio is close. 
Fletcher (5) stated that papillary microcarcinoma has been reported 
to show highly variable prevalence rate in different countries. The 
highest rate has been reported in Finland (35.6%) and the lowest in 
Switzerland (1.2%). Sources of these differences have attributed 
these findings to differences in diagnostic criteria and techniques of 
examination but a genetic factor is probably also responsible (5). 
The percentage of papillary microcarcinoma in the study was 16.7% 
( 2 cases), which fell within  the reported range above (1.2%- 35%). 
It is felt that more appropriate step sectioning of the thyroid samples 
may reveal a higher percentage than that reported in the study.  
In the study follicular carcinoma (Fig. 10) constituted 33.3% (9 
cases) of thyroid malignancies coming next to papillary carcinoma 
(Table 12). The peak age of incidence of follicular carcinoma was 60 
to < 70 years (33.3%). Eleven percent (11.1%) occurred in <30 
years, 44.4% occurred in the age group 30 to < 50 years and 66.6% 
occurred in >50years   (Table 17 and Figure 4). The mean age for 
follicular carcinoma was 51.2 years. The minimum was 27 years and 
the maximum 70 years with a range of 43 years (Table 15). Of the 9 
cases of follicular carcinoma in this study one was a male and 8 were 
females. The male to female ratio was 1:8 (Table 14).  
Sternberg(17) reported that follicular carcinoma comprised about 5% 
of thyroid cancers. However in iodine deficient areas this tumor is 
more prevalent making up to 25% to 40% of thyroid  cancers (17). 
The true incidence of follicular carcinoma is difficult to determine 
since the follicular variant of papillary carcinoma may still placed 
into this category. Follicular carcinoma generally affects patients 
with a higher mean age compared with follicular adenoma. The 
mean age of follicular carcinoma at diagnosis is 48-55 years with a 
male to female ratio of 1:1.25 to 1:4 (5 ).   
In this study the frequency of follicular carcinoma fell within the 
range of iodine deficient areas. It is known that iodine deficiency is 
prevalent in  some areas of Sudan(42). The mean age of incidence 
also fell within that reported by Fletcher(5 ) above. There is as well 
concordance in the higher prevalence of this malignancy in females. 
The male to female ratio in this study was 1:8 which is totally 
different from that reported by Fletcher(5). This difference may be 
due to the small number of follicular carcinomas (one male and 8 
females) analyzed in this study. More study of larger samples is 
needed  to evaluate the male to female ratio in Sudanese patients.  
In reference to Table 12 and Figure 5, medullary carcinoma (Fig.11) 
constituted 11.1% (3 cases) of all thyroid malignancies diagnosed in 
this study. All cases occurred in the group 20 to <60 years.  No case 
was diagnosed in the age groups below 20 years or >60years (Table 
18). Medullary carcinoma was more common in females (66.7%) 
than males (33.3%) with a male to female ratio of 1:2(Table 14). The 
mean age of occurrence was 39.7 years and the age span was 29-55 
years with a range of 26 years (Table 15). Fletcher(5) stated that 
medullary carcinoma comprises 5 to 10 % of all thyroid 
malignancies and the mean age at diagnosis for sporadic medullary 
thyroid carcinoma (MTC) is 44-50 years and for familial MTC 41-
43 years. The male to female ratio for sporadic MTC is 1:1.4 and 
that for familial MTC 1:1.1.  
The prevalence of medullary carcinoma in the study (11.1%) is a 
little bit higher, but the upper age limit and the male to female ratio 
are close to that reported by Fletcher. But the age range, the mean 
age and male to female ratio are all different for both sporadic and 
familial cases(5). 
Since the study did not differentiate between sporadic and  familial 
cases of medullary carcinomas this may be the cause of such 
differences. Moreover these differences may be due to misdiagnosis 
of medullary carcinoma due to uncommon utilization of 
immunohistochemistry to confirm the diagnosis of medullary 
carcinoma. Three  cases were analyzed in this study.  the small 
sample size may also contribute to these differences. 
In reference to Table 12 and Figure 6, anaplastic carcinoma (Fig.12) 
constituted 11.1% (3 cases) of all thyroid malignancies. All cases in 
the study occurred in the age 40 to < 90 years (Table 19). The mean 
age of occurrence was 58.3 years. The minimum and maximum ages 
were 40 and 80 years respectively (Table 15). Anaplastic carcinoma 
was diagnosed only in females in the study (Table 14).  
Fletcher (5) stated that anaplastic carcinoma comprises 3-5% of all 
thyroid carcinomas, however it may account for up to 30-40 % in 
places where goiter is endemic. It occurs more commonly in females 
with a male to female ratio of 1:1.1 to 1: 1.4. The mean age of 
incidence is 66.6 years (5). Also Ordonez et al (25) stated that 
anaplastic carcinoma occurs mainly in the elderly, only 25% of 
patients are younger than 60 years at diagnosis.  
The study showed that anaplastic carcinoma occurrence (11.1%) fell 
between the endemic (30-40) and non-endemic rate ratio (3-5%) as 
reprted by Fletcher(5) . This issue needs more evaluation. 
The mean age of anaplastic carcinoma in the study was less than that 
reported by Fletcher (5). As all the patients in the study were  
females who were expected to report lesser age than actual, it may 
be the cause behind the reduced mean age. As there was no male 
case of anaplastic carcinoma diagnosed in this study, this supports 
the predominance of anaplastic carcinoma in females. All cases were 
between 40 to 80 years old, which is in concordance with the 
occurrence of anaplastic carcinoma in elderly. 
Following Fletcher (5) classification of primary thyroid cancers 
according to behavior, thyroid cancers in the study were 52 % of low 
grade malignancy, 37% of intermediate grade malignancy and 
11.1% were of high grade malignancy (Table 20). No similar studies 
were found to compare these results with.  
Table 21, shows that anterior neck swelling was the presenting 
symptom in 61.9%. As we expect that most thyroid tumors present 
with anterior neck swelling, this lower percentage is probably due to 
deficient documentation. 
 Hoarseness of voice was the presenting symptom in one case. 
Dysphasia and dyspnea each was recorded only once. The 
explanation of deficient clinical presentations is probably the lack of 
proper documentation. 
In reference to Table 22, regarding the methods of diagnosis used in 
the cases of the study it can be noted that surgical biopsy was done 
for all cases. However weather it was a primary or secondary 
operation or was guided by prior FNABs was not mentioned. The 
highest proportion of the operations was unspecified thyroidectomy 
(56.7%) followed by lobectomy (22.7%), subtotal thyroidectomy 
(11.3%), excisional biopsy (7.2%) and total thyroidectomy (2.1%). 
The very high number of unspecified operations makes the 
evaluation of surgical intervention unfeasible. As reported by 
Ackerman(11), In cases in which nodule is limited to one lobe, 
lobectomy (with or without isthmusectomy) is usually done as the 
first approach, with subsequent therapy depending on the nature of 
the nodule and nodulectomy is no longer an accepted form of 
therapy for these lesions(11). In the study 7.2% of cases underwent 
excisional biopsy. This is no longer an accepted trend (11).   
FNABs was done for 14 cases (14.4%) out of the 97 cases (Table 
22). The result of  these 14 cases was; colloid nodule constituted 
21.4%(3 cases),  anaplastic carcinoma 14.3%(2 cases), suspicious 
tumor 14.3% (2 cases), malignant tumor 21.4% (3 cases) and benign 
tumor constituted 28.6% (4 cases),(Table 23). No papillary 
carcinoma was diagnosed by FNAB. Delellis et al (2) reported that, 
in most large series of FNABs studies 70% (50-90%) are benign, 
4%(1-10%) are malignant, 10%(5-20%) are 
indeterminate/suspicious and 16%(15-20%) are unsatisfactory. 
In the study the benign category constitutes 50% which is the 
minimum of the Delellis et al figure(2), but the malignant category 
constitutes 35.7 % which is very high compared to that reported by 
Delellis et al (2), and the suspicious category constitutes 14.3% 
which is within the reported frequency. The study also showed that 
the classification of the results of FNABs in the studied cases were 
not consistent with that used by the WHO(World Health 
Organization(2). Accordingly the proportion of malignancy 
diagnosed by FNABs in the study was very high. These findings 
reflect the need for revising the FNAB criteria for diagnosis and 
interpretation of thyroid tumors. The role of FNABs as guidance for 
primary thyroid tumor surgery also needs consideration since 
surgery is recommended for lesions classified as malignant or 
indeterminate/suspicious while those patients with benign smears are 
generally followed up and reboots is recommended for patients with 
non-diagnostic aspirates(2).  
Ultrasound is particularly useful for establishing the size of a lesion 
and its solid or cystic nature as well as for guiding the performance 
of  FNAB. CT scan and MRI are preferable to ultrasound when 
tracheal or mediastinal invasion are suspected and also for 
metastases (2 ). Such a role of ultrasound in the studied cases was 
not noted. This means that there is a need for more utilization of 
ultrasound in thyroid tumor management.  
Although scintigraphy was not found to be used in the studied cases, 
but still it can have a good role in clinical evaluation of thyroid 
nodules since the nodules that take up radioactive iodine i.e. hot 
nodules are more likely to be benign than malignant(1). 
Serum calcitonin is used routinely in the diagnosis and follow up of 
cases with medullary carcinoma (2). It was not used in the cases of 
medullary carcinoma or other cases in the study. 
Immunohistochemistry, thyroglobulin and TTF-1 was not used at all 
in any case in the study. So the diagnosis of thyroid tumors relied 
mainly on histological features. In metastasis as in undifferentiated 
thyroid carcinomas, the immunohistochemistry is very important. 
Such trend may lead to misdiagnosis as the histological patterns of 
thyroid carcinomas overlap and may explain the lack of diagnosing 
metastases in this study. 
Chan JKC et al (14) reported that the epidemiology of thyroid tumors 
is difficult to analyze and shows  variations between different 
regions and countries, because of the lack of consistent criteria  for 
distinguishing hyperplasic nodules and adenomas. The study 
revealed that the epidemiology of thyroid tumors in Sudan cannot be 
analyzed satisfactorily because there is total deficiency of reporting 
relevant data concerning risk factors, demographic data, treating 
units and means of communications with patients or their treating 
units. This issue is of special concerns as the epidemiology of 
thyroid tumors - and most likely other tumors - will continue to be 
deficient.  
 
 
 
 
 
 
 
4-2 CONCLUSION 
 
When all the findings in the study are considered together, it can be said 
that the histologic pattern of thyroid tumors, the sex and age distributions 
in the study tend to correspond with studies in other countries. 
The study shows that the ratio of follicular adenoma relative to thyroid 
carcinomas  is 3:1. This result is  one third of that reported by Robbins(1) 
which is 10:1. This difference may be  explained by the small number of 
thyroid tumors analyzed since not all thyroid samples are sent to 
histopathological examination. Another probable  reason may be that 
there is more tendency to diagnose hyperplasic nodule rather than 
follicular adenoma. Also there may be cases of follicular adenoma missed 
within multinodular goiter cases.  This issue needs further evaluation.   
 Follicular carcinoma analysis in the study revealed a higher male to 
female ratio (1:8) compared to that reported by Fletcher(5), which is 1:4.  
This awaits further evaluation. 
 
FNAB results in the study showed a higher percentage of diagnosing 
thyroid malignancies compared to Delellis et al(2) results of FNABs 
examination. This finding entails revising the criteria of diagnosis and 
interpretation of  FNAB in the management of thyroid nodules in Sudan. 
 
The study revealed that immunohistochemical markers as well as  serum 
calcitonin level  were not used at all in the analyzed cases. There is a real 
need for providing at least the important markers such as thyrogobulin, 
calcitonin etc. 
 
The study showed that the reporting of epidemiological data is very poor 
especially the demographic data and those data concerning the risk 
factors. Therefore evaluation of the epidemiology of thyroid  
malignancies and the tumors distribution among different ethnic groups 
and residences could not be performed. 
 
Literature review revealed lack of national studies concerning 
epidemiology and clinico-pathological aspects of thyroid diseases. The 
thyroid gland which is the commonest endocrine gland to be involved by 
malignancy needs more research and study. 
 
Since more health education and transportation systems are being 
established, one will expect more cases of goiter samples to be received 
for histopathological examination.     
 
4-3 RECOMMENDATION 
 
A more detailed assessment of thyroid tumors awaits good and 
complete data reporting otherwise the epidemiology and clinico-
pathological aspects of thyroid tumors can not be evaluated. More 
research needs  to be carried out to address possible environmental 
and community related risk factors. 
 
The criteria and the role of FNAB in diagnosing and management of 
thyroid tumors need to be reviewed in this era of  increasing use and 
availability of thyroid cytopathology.  
 
The use of nodulectomy must be avoided, as it is  currently not an 
accepted procedure in the management of thyroid nodules. 
 
Proper data documentation should be established soon, and unified 
request form should be designed and implemented. Incompletely 
filled forms should be rejected even if this require formal 
legislations, otherwise the epidemiology of thyroid tumors and also 
other tumors will continue to be lost. 
 
More co-operation and co-ordination between laboratories and 
treating units is highly recommended otherwise a proper evaluation 
of epidemiology, diagnosis, treatment and the outcome of thyroid 
tumors could not be obtained. 
Thyroid samples need proper handling particularly in sectioning as 
the criteria to differentiate between follicular carcinoma and 
follicular adenoma largely depend on the demonstration of a capsule. 
Papillary microcarcinoma needs proper sectioning to be detected. It 
is felt that appropriate sectioning may reveal more cases of papillary 
micro carcinoma than reported in the study.   
 
Provision of thyroid immunohistochemical markers are highly 
recommended.  
 
Storage of slides and blocks require special care as they are highly  
valuable material. 
More studies of  thyroid gland pathology are highly recommended as 
the national data concerning  thyroid gland tumors are deficient. 
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APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
University of Khartoum -Faculty of Medicine 
Postgraduate Medical Students Board 
Questionnaire 
Thyroid Tumors 
 
 
Date: / /          Serial No:  
Hospital: 1- Soba                2- RIC                            3- NHL (Khartoum)   
* Lab NO: ………………. consultant in charge ……………………File NO 
………………….. 
1- Name ……………………………2-Adress …………         3-Age (in 
years)………… 
4-Gender  a- Male                 b- Female  
5- Tribe ………… 6- Occupation …………7- Residence …………8- Origin ………….. 
9- Risk factors: History of: 
 
 
 a-Diagnostic X-Ray  for  the neck     yes              when (in years)               
 
                                        No               Not Known              
 b-Therapeutic irradiation involving  the head, neck and upper mediastinum    
            Yes              when (in years)                   no        not know                        
10-    Clinical remarks:  
a-ant. neck swelling:.  Yes                Painful            painless           
  no  other (specify)  specify ……………. 
 
- hoarsness      Yes                 No                -dysphagia  yes   no   
 
- dyspnea       Yes                 No                    cough  yes      no   
 
- hemoptysis    Yes                 No                           
     - Others            Yes         specify      …………………………              No 
11- Diagnosed by: 
 a- FNACs      Yes               No 
   
 b- Surgical resection biopsy    Yes             No  
             
c- Imaging:  CT scan             result………..          U/S                result…………. 
 
 d-- Radionuclide iodine scan  result………   iv- MRI             result…….. 
12-  TFT : TSH   T3      T4  Thyroglobulin conc. 
13-  Immunohistochemistry   yes   result……………………no   
14- S .calcitono… yes   result…………………….…no   
15-  amyloid stain   yes  result………………………..no   
16- Other investigation  specify ……………………result…………………. 
 
17- FNACs finding: ……………………………… 
18- Histopathology: 
 Type of specimen   excisiononal            incisional        subtotal 
 nearly total               Total thyroidectomy              
 Gross:…………………………………………… 
 Microscopy:……………………………………. 
 Diagnosis:……………………………………… 
 Grading:………………………………………… 
 
 
 
 
 
 
